<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7485091</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.02163</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sanclemente-Alaman</surname><given-names>Inmaculada</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><xref ref-type="author-notes" rid="fn003"><sup>&#x02021;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1010806/overview"/></contrib><contrib contrib-type="author"><name><surname>Moreno-Jim&#x000e9;nez</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><xref ref-type="author-notes" rid="fn003"><sup>&#x02021;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1010025/overview"/></contrib><contrib contrib-type="author"><name><surname>Benito-Mart&#x000ed;n</surname><given-names>Mar&#x000ed;a Soledad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Canales-Aguirre</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/46548/overview"/></contrib><contrib contrib-type="author"><name><surname>Mat&#x000ed;as-Guiu</surname><given-names>Jordi A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/252696/overview"/></contrib><contrib contrib-type="author"><name><surname>Mat&#x000ed;as-Guiu</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/254118/overview"/></contrib><contrib contrib-type="author"><name><surname>G&#x000f3;mez-Pinedo</surname><given-names>Ulises</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/363959/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Neurobiology, Department of Neurology, Institute of Neurosciences, San Carlos Institute for Health Research, Universidad Complutense de Madrid</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff2"><sup>2</sup><institution>Preclinical Evaluation Unit, Medical and Pharmaceutical Biotechnology, CIATEJ-CONACYT</institution>, <addr-line>Guadalajara</addr-line>, <country>Mexico</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Bruno Stankoff, Sorbonne Universit&#x000e9;, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Yoshiro Ohara, Kanazawa Medical University, Japan; Jorge Correale, Fundaci&#x000f3;n para la Lucha Contra las Enfermedades Neurol&#x000f3;gicas de la Infancia (FLENI), Argentina</p></fn><corresp id="c001">*Correspondence: Ulises G&#x000f3;mez-Pinedo, <email>u.gomez.pinedo@gmail.com</email></corresp><fn fn-type="other" id="fn002"><p><sup>&#x02020;</sup>ORCID: Inmaculada Sanclemente-Alaman, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-1847-547X">orcid.org/0000-0003-1847-547X</ext-link>; Lidia Moreno-Jim&#x000e9;nez, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-2730-4130">orcid.org/0000-0002-2730-4130</ext-link>; Mar&#x000ed;a Soledad Benito-Mart&#x000ed;n <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-6131-6426">orcid.org/0000-0002-6131-6426</ext-link>; Alejandro Canales-Aguirre, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0003-0918-788X">orcid.org/0000-0003-0918-788X</ext-link>; Jordi A. Mat&#x000ed;as-Guiu, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-5520-2708">orcid.org/0000-0001-5520-2708</ext-link>; Jorge Mat&#x000ed;as-Guiu, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-8162-9043">orcid.org/0000-0001-8162-9043</ext-link>; Ulises G&#x000f3;mez-Pinedo, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0003-3097-5557">orcid.org/0000-0003-3097-5557</ext-link></p></fn><fn fn-type="other" id="fn003"><p><sup>&#x02021;</sup>Both authors are considered lead authors with the same responsibility</p></fn><fn fn-type="other" id="fn004"><p>This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>2163</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Sanclemente-Alaman, Moreno-Jim&#x000e9;nez, Benito-Mart&#x000ed;n, Canales-Aguirre, Mat&#x000ed;as-Guiu, Mat&#x000ed;as-Guiu and G&#x000f3;mez-Pinedo.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Sanclemente-Alaman, Moreno-Jim&#x000e9;nez, Benito-Mart&#x000ed;n, Canales-Aguirre, Mat&#x000ed;as-Guiu, Mat&#x000ed;as-Guiu and G&#x000f3;mez-Pinedo</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The response to the SARS-CoV-2 coronavirus epidemic requires increased research efforts to expand our knowledge of the disease. Questions related to infection rates and mechanisms, the possibility of reinfection, and potential therapeutic approaches require us not only to use the experimental models previously employed for the SARS-CoV and MERS-CoV coronaviruses but also to generate new models to respond to urgent questions.</p></sec><sec><title>Development</title><p>We reviewed the different experimental models used in the study of central nervous system (CNS) involvement in COVID-19 both in different cell lines that have enabled identification of the virus&#x02019; action mechanisms and in animal models (mice, rats, hamsters, ferrets, and primates) inoculated with the virus. Specifically, we reviewed models used to assess the presence and effects of SARS-CoV-2 on the CNS, including neural cell lines, animal models such as mouse hepatitis virus CoV (especially the 59 strain), and the use of brain organoids.</p></sec><sec><title>Conclusion</title><p>Given the clear need to increase our understanding of SARS-CoV-2, as well as its potential effects on the CNS, we must endeavor to obtain new information with cellular or animal models, with an appropriate resemblance between models and human patients.</p></sec></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>experimental models</kwd><kwd>COVID-19</kwd><kwd>central nervous system</kwd><kwd>neurodegenerative disease</kwd><kwd>multiple sclerosis</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="156"/><page-count count="12"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>On 31 December 2019, the Word Health Organization reported for the first time on an epidemic of lower respiratory tract infection in Wuhan, in the Chinese province of Hubei. The causal agent was soon identified as Severe acute respiratory syndrome coronavirus (SARS-CoV-2), a coronavirus (CoV), and the associated disease was named coronavirus disease 19 (COVID-19) (<xref rid="B1" ref-type="bibr">1</xref>). CoVs are positive-sense single-stranded RNA viruses resembling a crown under microscopy due to the presence of spike (S) glycoproteins on the viral envelope. There are four types of CoVs: &#x003b1;CoVs, &#x003b2;CoVs, &#x003b4;CoVs, and &#x003b3;CoVs. SARS-CoV, MERS-CoV, and SARS-CoV-2 are zoonotic (<xref rid="B2" ref-type="bibr">2</xref>), first infecting animals and then spreading to humans. &#x003b2;CoVs, which include SARS-CoV-2, are thought to originate in bats (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>), among other species. These viruses can cause respiratory and enteric diseases in different animal species. In humans, HCoV-OC43 and HCoV-HKU1 (&#x003b1;CoVs), and HCoV-229E and HCoV-NL63 (&#x003b2;CoVs) can cause the common cold and self-limiting infection of the lower respiratory tract in immunocompetent individuals in seasonal periods (<xref rid="B5" ref-type="bibr">5</xref>). Two previous epidemics have, however, been caused by CoVs; these were similar to the current pandemic, though with higher mortality rates, and were caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV) and affected many countries (<xref rid="B6" ref-type="bibr">6</xref>). Although they led to many research studies, expanding our knowledge of the viruses, the COVID-19 epidemic has had a far greater global impact. One as-yet unknown aspect of SARS-CoV-2 is its potential short- and long-term impact on the central nervous system. In this respect, although the rate of neurological symptoms associated with infection is not high (<xref rid="B7" ref-type="bibr">7</xref>), the possibility of subsequent effects of central nerve system (CNS) infection has been suggested by many authors (<xref rid="B8" ref-type="bibr">8</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>). To address these questions, we need experimental models based on advances in biomedical research both <italic>in vitro</italic> and <italic>in vivo</italic>. We review these models in the present article.</p></sec><sec id="S2"><title>Objectives of the Experimental Models in the Study of the Impact of SARS-CoV-2 Infection</title><p>Previous studies on SARS-CoV already demonstrated that the spike protein facilitates viral invasion of the target cell by interacting with the angiotensin converting enzyme 2 (ACE2) (<xref rid="B18" ref-type="bibr">18</xref>). This protein is expressed on the surface of epithelial cells of the lower respiratory tract, endothelial cells of arteries and veins, intestinal mucosa cells, kidney cells, immune cells, glial cells, and neurons (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). <italic>In vitro</italic> studies have demonstrated that SARS-CoV-2 also uses this receptor to penetrate cells (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). In fact, sequencing of the SARS-CoV-2 spike protein has shown that it contains residues that may increase its binding affinity to the ACE2 receptor 10- to 20-fold in comparison with SARS-CoV (<xref rid="B18" ref-type="bibr">18</xref>). When spike protein interacts with the receptor, cleavage and activation by cell proteases is necessary to enable the viral membrane to fuse with the host cell and the virus to penetrate. <italic>In vitro</italic> studies have shown that SARS-CoV-2 spike proteins are mainly processed by transmembrane protease serine 2 (<italic>TMPRSS2</italic>), by endosomal cathepsins B and L in the absence of <italic>TMPRSS2</italic> (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>), and by furin (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Once the virus is internalized, viral RNA is released into the cytoplasm, and a series of translations and replications create new RNAs and viral proteins that assemble to form new virions (<xref rid="B20" ref-type="bibr">20</xref>). These are released from the host cell and can infect new target cells expressing the appropriate receptor on their surfaces (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p><p>More complex biological systems are, however, needed to study the possible interactions between SARS-CoV-2 and the host. Due to these complex interactions, selecting an appropriate model should be a thoughtful and clearly defined process, in order to provide relevant and translatable scientific data enabling us to address the questions of interest and to ensure the rational use of animals. Although many animals may respond similarly to humans from physiological, pathological, and therapeutic perspectives, we must bear in mind that differences between species may lead to erroneous conclusions (<xref rid="B27" ref-type="bibr">27</xref>); it is therefore necessary to understand the relationship between the model and the human disease (<xref rid="B28" ref-type="bibr">28</xref>). In the light of the current pandemic, it is essential to have a cellular or animal model mimicking the symptoms and pathological processes identified in patients infected with SARS-CoV-2 (<xref rid="B29" ref-type="bibr">29</xref>).</p></sec><sec id="S3"><title><italic>In Vitro</italic> Models (<xref rid="T1" ref-type="table">Table 1</xref>)</title><sec id="S3.SS1"><title>Vero E6 Cell Line</title><p>This cell line was isolated from kidney epithelial cells extracted from an African green monkey (<italic>Chlorocebus aethiops</italic>) in 1979; the Vero E6 cell line has been shown to be very useful for viral propagation and production <italic>in vitro</italic> (<xref rid="B30" ref-type="bibr">30</xref>). These cells are permissive to SARS-CoV replication, as they efficiently express the ACE2 receptor (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Furthermore, they enable persistent infection <italic>in vitro</italic> (<xref rid="B33" ref-type="bibr">33</xref>). Vero E6 cells have therefore already been used in studies with SARS-CoV and MERS-CoV (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B33" ref-type="bibr">33</xref>&#x02013;<xref rid="B36" ref-type="bibr">36</xref>) and also in the development of live-attenuated and inactivated vaccines for human use (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). More recently, they have been used in research into the viral infection mechanism in COVID-19 (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>), the effects of the virus on cells, confirmation of viral infection (<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>) and pharmacological research (<xref rid="B44" ref-type="bibr">44</xref>&#x02013;<xref rid="B48" ref-type="bibr">48</xref>).</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p><italic>In vitro</italic> models for the study of SARS-CoV-2.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Cell Line</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Origin</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Virus Dose</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Use</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Vero E6</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">African green monkey (<italic>Chlorocebus aethiops</italic>) kidney epithelial cells</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>Multiplicity of infection (MOI) of 0.01 to 0.5</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<italic>In vitro</italic> amplification of viral particles<break/>&#x02022;Diagnosis of SARS-CoV-2 infection and viral isolation<break/>&#x02022;Study of infection mechanism<break/>&#x02022;Search for new therapeutic targets<break/>&#x02022;Pharmacological screening</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>HEK 293T</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Human embryonic kidney epithelial cells</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>No determined</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Study of infection mechanism<break/>&#x02022;Search for new therapeutic targets<break/>&#x02022;Pharmacological screening</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B39" ref-type="bibr">39</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>BHK-21</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Baby hamster (<italic>Mesocricetus auratus</italic>) kidney fibroblasts</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>8 &#x000d7; 10<sup>7</sup> genome equivalents (GE) per 24-well of SARS-CoV-2</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Study of infection mechanism</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B48" ref-type="bibr">48</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Huh7</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Human hepatocellular carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>MOI of 0.05 to 1</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Diagnosis of SARS-CoV-2 infection and viral isolation<break/>&#x02022;Study of infection mechanism<break/>&#x02022;Pharmacological screening</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B43" ref-type="bibr">43</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>LLC-MK2</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus macaque (<italic>Macaca mulatta</italic>) kidney epithelial cells</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>No determined</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Diagnosis of SARS-CoV-2 infection and viral isolation<break/>&#x02022;Study of infection mechanism</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Caco-2</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Human colorectal adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>No determined</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Study of infection mechanism</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B72" ref-type="bibr">72</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Calu-3</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Human lung adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>MOI of 0.001 to 0.08</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Study of infection mechanism<break/>&#x02022;Pharmacological screening</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B141" ref-type="bibr">141</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><bold><italic>Human brain organoids</italic></bold></td><td valign="top" align="left" rowspan="1" colspan="1">Human induced pluripotent stem cells (hIPSCs)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;<bold>MOI of 0.1 to 2.5</bold></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022;Nervous tissue infection mechanisms<break/>&#x02022;Neurodegenerative mechanisms<break/>&#x02022;Pharmacological screening</td></tr></tbody></table><table-wrap-foot><attrib><italic>The table includes the main cell lines used in the study of SARS-CoV-2 infection, the origin of the cells, viral dose used in some studies for the infection of cells and their uses. The culture media used for each cell line is specified in <xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</italic></attrib></table-wrap-foot></table-wrap></sec><sec id="S3.SS2"><title>HEK 293T Cell Line</title><p>This cell line is a variant of the HEK 293 lineage, which was isolated from kidney epithelial cells extracted from human embryos (<xref rid="B49" ref-type="bibr">49</xref>). Both lines are widely used in research due to their high transfectability, gene expression, and production of proteins or recombinant retrovirus (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). The HEK 293T variant expresses the T SV-40 antigen, which enables the amplification of transfected plasmids containing the SV40 origin of replication and thus considerably increases the expression levels of desired gene products (<xref rid="B50" ref-type="bibr">50</xref>). These cells have also previously been used in studies of other such viruses as herpes simplex virus, SARS-CoV, and even CoV pseudovirions (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B51" ref-type="bibr">51</xref>&#x02013;<xref rid="B53" ref-type="bibr">53</xref>). Due to its high efficiency of transfection, research with this cell line is producing significant findings, such as the confirmation of ACE2 as the cell entry receptor for SARS-CoV-2 and the potential role of CD147 as an alternative receptor (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>).</p></sec><sec id="S3.SS3"><title>BHK-21 Cell Line</title><p>This line is a subclone of the fibroblast cell line extracted from 1-day-old Syrian hamster (<italic>Mesocricetus auratus</italic>) kidney cells (<xref rid="B54" ref-type="bibr">54</xref>) and is useful for studying virus propagation and plasmid transfection (<xref rid="B55" ref-type="bibr">55</xref>). It has been used in the study of HCoV-OC43 and SARS-CoV-2 infection mechanisms (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>).</p></sec><sec id="S3.SS4"><title>Huh7 Cell Line</title><p>This lineage was established in 1982 from a human hepatocellular carcinoma; it is therefore able to produce a great variety of substances secreted by the human liver (<xref rid="B58" ref-type="bibr">58</xref>) and has been used in the study of hepatitis C virus, SARS-CoV, and MERS-CoV (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). In the context of SARS-CoV-2, this cell line has been used in the study of infection mechanisms (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B39" ref-type="bibr">39</xref>), the cytotoxicity of viruses from human hosts (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B60" ref-type="bibr">60</xref>), and in pharmacological research (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B48" ref-type="bibr">48</xref>).</p></sec><sec id="S3.SS5"><title>LLC-MK2 Cell Line</title><p>The LLC-MK2 cell line was established in 1955 from rhesus macaque (<italic>Macaca mulatta</italic>) kidney epithelial cells (<xref rid="B61" ref-type="bibr">61</xref>). It has been mainly used in the study of poliovirus, but also to study SARS-CoV, HCoV-NL63 (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), and SARS-CoV-2 to assess the cytopathic effects in patients infected with the virus (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B43" ref-type="bibr">43</xref>) and to characterize its viral infectious pathway (<xref rid="B39" ref-type="bibr">39</xref>).</p></sec><sec id="S3.SS6"><title>Caco-2 Cell Line</title><p>This line was extracted in 1977 from human epithelial colorectal adenocarcinoma cells; under specific culture conditions, the cells are able to differentiate into small intestine enterocytes (<xref rid="B64" ref-type="bibr">64</xref>). This cell line is frequently used to study transfection, invasion, and absorption (<xref rid="B65" ref-type="bibr">65</xref>). It has been used in studies of MERS-CoV, SARS-CoV, and HCoV-NL63 (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>), and in the analysis of the S protein activation in studies with SARS-CoV-2, due to the fact that these cells express the TMPRSS2 protease (<xref rid="B23" ref-type="bibr">23</xref>).</p></sec><sec id="S3.SS7"><title>Calu-3 Cell Line</title><p>This line was extracted in 1975 from a human lung adenocarcinoma and is used in the study of respiratory viruses (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). It has been used in the study of SARS-CoV and MERS-CoV (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>) and infection mechanisms studies and pharmacological research into COVID-19 (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B72" ref-type="bibr">72</xref>).</p></sec><sec id="S3.SS8"><title>Other Cell Lines</title><p>Several of the available cell lines susceptible to transfection may also be used in <italic>in vitro</italic> research. For example, the study by Zhou et al. (<xref rid="B22" ref-type="bibr">22</xref>) uses the <italic>HeLa</italic> cell line, which does not endogenously express ACE2, and expression plasmids for human ACE2 (hACE2) in the study of SARS-CoV-2.</p></sec></sec><sec id="S4"><title><italic>In Vivo</italic> Models (<xref rid="T2" ref-type="table">Table 2</xref>)</title><p>Mouse and hamster strains are the main animal models used in research into SARS-CoV and MERS-CoV (<xref rid="B73" ref-type="bibr">73</xref>); however, in the case of SARS-CoV-2, research efforts have been focused on the study of aged mouse strains, the design of humanized mouse models that express the hACE2 receptor, and the creation of knockout mice, with the aim of replicating the mechanisms involved in human infection.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p><italic>In vivo</italic> models for the study of SARS-CoV-2 infection in the CNS.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Model</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Virus, inoculation route, and dose</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Findings</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 <italic>ACE2</italic> knockout mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV; intranasal; 7.6 &#x000d7; 10<sup>6</sup> pfu/ml in DMEM</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanisms of primary infection and viral propagation</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">73</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 <italic>TMPRSS2</italic>&#x02013;/&#x02013; knockout mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV; intranasal; 10<sup>5</sup> TCID<sub>50</sub> in F-musX MERS-CoV; intranasal; 10<sup>6</sup> TCID<sub>50</sub> in HCoV-EMC 2012</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanisms of primary infection and viral propagation in the respiratory tracts</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B85" ref-type="bibr">85</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 <italic>STAT1</italic> knockout mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV, SARS-CoV 2; intranasal 7 &#x000d7; 10<sup>4</sup> pfu</td><td valign="top" align="left" rowspan="1" colspan="1">Cytokine-induced biological responses</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">hACE2 ICR mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intranasal; 10<sup>5</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Viral antigen in the lower respiratory tract, alveolar infiltrates, and weight loss</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">80</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6J-hACE2-AAV mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intranasal; 3 &#x000d7; 10<sup>7</sup> pfu/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary infiltrate, neutralizing antibodies, interferon-stimulated genes</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 young and aged hACE2 mouse</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intranasal; 4 &#x000d7; 10<sup>5</sup> pfu. Intragastric; 4 &#x000d7; 10<sup>6</sup> pfu</td><td valign="top" align="left" rowspan="1" colspan="1">Viral antigen in trachea, lungs, and brain. Pulmonary infiltrate. Pathological changes in lungs are more evident in aged mice.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B88" ref-type="bibr">88</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Young and aged BALB/c mouse</td><td valign="top" align="left" rowspan="1" colspan="1">Adapted viruses: SARS-CoV-2 MA; intranasal; 10<sup>5</sup> pfu</td><td valign="top" align="left" rowspan="1" colspan="1">Viral replication in lower and upper respiratory tract. Clinical symptoms worsen with age. Prophylactic and therapeutic role of interferon lambda-1a</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">87</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Young and aged BALB/cC57 mouse Young C57BL/6 mouse</td><td valign="top" align="left" rowspan="1" colspan="1">Adapted viruses: SARS-CoV-2 MASCp6; intranasal; 7.2 &#x000d7; 10<sup>5</sup> pfu Adapted viruses: SARS-CoV-2 MASCp6; intranasal; 7.2 &#x000d7; 10<sup>5</sup> pfu</td><td valign="top" align="left" rowspan="1" colspan="1">Evaluation of the efficacy of the subunit vaccine consisting of SARS-CoV-2 S protein RBD fused with a human IgG Fc subunit</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">92</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Syrian hamster (<italic>Mesocricetus auratus</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intranasal; 8 &#x000d7; 10<sup>4</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Viral antigen in the upper and lower respiratory tracts and intestinal mucosa. Pulmonary infiltrates. Neutralizing antibodies. Transmission by direct contact or aerosols</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B148" ref-type="bibr">148</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mouse</td><td valign="top" align="left" rowspan="1" colspan="1">MHV coronavirus; intranasal, intracerebral, enteral (1&#x02013;2.5 &#x000d7; 10<sup>3</sup>pfu)</td><td valign="top" align="left" rowspan="1" colspan="1">Mechanisms of primary infection and viral propagation, demyelinating lesion model</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B93" ref-type="bibr">93</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Syrian hamster (<italic>Mesocricetus auratus</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intranasal; 10<sup>5</sup> pfu in DMEM</td><td valign="top" align="left" rowspan="1" colspan="1">Viral antigen in the upper and lower respiratory tracts and intestinal mucosa. Mononuclear infiltrates. Neutralizing antibodies. Transmission by direct contact</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B97" ref-type="bibr">97</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Mustela putorius furo</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 F13-E and SARS-CoV-2 CTan-H; intranasal; 10<sup>5</sup>pfu</td><td valign="top" align="left" rowspan="1" colspan="1">Viral replication in the upper respiratory tract without causing severe disease</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B98" ref-type="bibr">98</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Mustela putorius furo</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 GISAID ID EPI_ISL 406862; intranasal; 6 &#x000d7; 10<sup>5</sup> TCID<sub>50</sub> of SARS-CoV2 virus diluted in 500 &#x003bc;l of PBS</td><td valign="top" align="left" rowspan="1" colspan="1">Direct and indirect transmission</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B96" ref-type="bibr">96</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Mustela putorius furo</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV strain Toronto-2; intranasal; 10<sup>3</sup>TCID<sub>50</sub>/mL diluted in medium</td><td valign="top" align="left" rowspan="1" colspan="1">Transmission before peak viral load, without symptom onset</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B105" ref-type="bibr">105</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca fascicularis</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 # 026V-03883, MERS-CoV # 011V-02838; intratracheal, intranasal; 10e<sup>6</sup> TCID<sub>50</sub> in PBS</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical symptoms similar to COVID-19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B100" ref-type="bibr">100</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 HB-01; intratracheal; 10<sup>6</sup> TCID<sub>50</sub>/mL</td><td valign="top" align="left" rowspan="1" colspan="1">More severe clinical symptoms in older monkeys</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B106" ref-type="bibr">106</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 MN985325.1; intratracheal, intranasal, conjunctival, oral; 4 &#x000d7; 10<sup>5</sup> TCID<sub>50</sub>/ml of DMEM</td><td valign="top" align="left" rowspan="1" colspan="1">Significant increase in pro-inflammatory interleukins</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B109" ref-type="bibr">109</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 WH-09/human/2020/CHN; conjunctival; 1 &#x000d7; 10<sup>6</sup> TCID<sub>50</sub>/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Viral load in the ocular system and respiratory and digestive tracts</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B107" ref-type="bibr">107</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta/Macaca fascicularis/Callithrix jacchus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intratracheal, intranasal, conjunctival; 10<sup>6</sup> pfu/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus monkey is more susceptible to infection.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B110" ref-type="bibr">110</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV strain HCoV-EMC/2012; intratracheal; 7 &#x000d7; 10<sup>6</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Viral RNA in the throat soon after infection</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B111" ref-type="bibr">111</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2/WH-09/human/2020/CHN; intratracheal; 1 &#x000d7; 10<sup>6</sup> TCID<sub>50</sub>/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus monkeys present no reinfection</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B112" ref-type="bibr">112</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 NR-52281; intratracheal, intranasal; 1.1 &#x000d7; 10<sup>6</sup> pfu or 1.1 &#x000d7; 10<sup>5</sup> pfu or 1.1 &#x000d7; 10<sup>4</sup> pfu</td><td valign="top" align="left" rowspan="1" colspan="1">No reinfection</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">113</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 MN985325.1; intratracheal, intranasal, conjunctival, oral; 2.6 &#x000d7; 10<sup>6</sup> TCID<sup>50</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Treatment study</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B115" ref-type="bibr">115</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Macaca mulatta</italic></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2; intratracheal; 10<sup>6</sup> TCID<sub>50</sub>/ml</td><td valign="top" align="left" rowspan="1" colspan="1">Vaccine development</td></tr></tbody></table><table-wrap-foot><attrib><italic>The table includes the characteristics of the animals (species) used, as well as the route of administration, viral dose used in some studies for the infection and the relevance of the model in SARS-CoV-2 research. <italic>TCID50</italic>, 50% tissue culture infectious dose; <italic>pfu</italic>, plaque forming units.</italic></attrib></table-wrap-foot></table-wrap><sec id="S4.SS1"><title>Aged Mouse Strains</title><p>Roberts et al. (<xref rid="B74" ref-type="bibr">74</xref>) reported that aged BALB/c mouse strains were able to maintain high rates of viral replication, which was associated with clinical illness and pneumonia; the study demonstrated an age-related susceptibility to SARS disease in animals that parallels the human experience. Advanced age has been identified as an independent factor of poor prognosis in COVID-19 and is considered a predictor of mortality in patients with SARS-CoV-2 infection. Other strains like C57BL/6 have also been used (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec><sec id="S4.SS2"><title>Knockout Mouse Models</title><p>K18-hACE2 transgenic mice express hACE2, with regulation by the human cytokeratin 18 (K18) promoter. Specifically, these mice contain 2.5 kb of the K18 genomic sequence, including the promoter, the first intron, and a translation-promoting sequence. Expression of hACE2 is mainly observed in the epithelium of the respiratory tract, which shows a higher incidence of SARS-CoV-2 infection, and in the epithelium of other organs, including the liver, kidneys, and gastrointestinal tract (<xref rid="B76" ref-type="bibr">76</xref>). K18-hACE2 mice infected with SARS-CoV-2 show weight loss and viral replication in the lungs, as in humans. Furthermore, they show the typical histopathological findings of interstitial pneumonia with lymphocytic and monocytic infiltration into the alveolar interstitium and an accumulation of macrophages in the alveolar cavities. Alveolar and bronchial epithelial cells show presence of viral antigens; this is not observed in wild-type (WT) mice with SARS-CoV-2 infection. Furthermore, these mice show other pathological changes, such as vasculitis, degeneration, and necrosis of extrapulmonary organs and presence of the viral antigen in the brain (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Bao et al. (<xref rid="B79" ref-type="bibr">79</xref>) recently studied the pathogenicity of SARS-CoV-2 virus in hACE2-expressing ICR transgenic mice and WT mice. This model may be useful in research into drug treatments for COVID-19. Israelow et al. (<xref rid="B80" ref-type="bibr">80</xref>) developed an hACE2-adeno-associated virus 9 (AAV) murine model, which was subsequently intranasally infected with SARS-CoV-2. They studied the presence of coronavirus infection, the inflammatory response in the lungs, the presence of neutralizing antibodies, and the type I interferon signaling pathway. The authors reported that this model would be very useful for understanding questions related to infection, replication, and pathogenesis of SARS-CoV-2 and for testing therapeutic strategies.</p><p>Sun et al. (<xref rid="B81" ref-type="bibr">81</xref>) used <italic>CRISPR/Cas9</italic> technology to create a murine hACE2 model in young and aged animals. After intranasal infection of the animals with SARS-CoV-2, the researchers observed viral replication in the lungs, trachea, and brain of both animals. However, alveolar inflammatory infiltrate and vascular lesions were more evident in aged animals; this is analogous to the pathological changes observed in older patients with COVID-19. This model also showed evidence of respiratory tract infection following intragastric inoculation.</p></sec><sec id="S4.SS3"><title><italic>TMPRSS2</italic>&#x02013;/&#x02013; Knockout Mice</title><p>This model was designed using a directional vector to replace exons 10&#x02013;13, which codify the serine protease domain of the <italic>TMPRSS2</italic> gene. It was constructed by electroporation of embryonic stem cells and their subsequent injection into C57BL/6 blastocysts for at least five generations (<xref rid="B82" ref-type="bibr">82</xref>). After experimental infection with SARS-CoV-2, <italic>TMPRSS2</italic>-deficient mouse strains showed reduced body weight loss and viral kinetics in the lungs. Absence of <italic>TMPRSS2</italic> affected the infection sites and virus spread within the respiratory tract; therefore, this is a useful model for COVID-19 research (<xref rid="B73" ref-type="bibr">73</xref>).</p></sec><sec id="S4.SS4"><title>The <italic>STAT1</italic> Knockout Mouse Model</title><p>(129S6/SvEv-STAT1tmRDS) contains a homozygous <italic>STAT1</italic> mutation and completely lacks functional <italic>STAT1</italic> proteins (Pgm1c and Gpi1b alleles of 129S6). The model was created by targeting the <italic>STAT1</italic> gene in GS-1 ES cells and injecting target cells into blastocysts. Heterozygous models of the mutation were produced from the chimeras and were crossed over to generate homozygous models (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). The <italic>JAK-STAT</italic> signaling pathway is involved in the mediation of cytokine-induced biological responses. This is therefore a useful model for determining the role of a variety of cytokines in immune responses, the role of <italic>STAT1</italic> protein in mediating interferon-dependent responses, and its relationship with viral and bacterial pathogens (<xref rid="B84" ref-type="bibr">84</xref>&#x02013;<xref rid="B86" ref-type="bibr">86</xref>); the model is also interesting in the analysis of SARS-CoV-2 inflammation mechanisms.</p></sec><sec id="S4.SS5"><title>Adapted Mouse Models</title><p>Studies have been recently conducted with BALB/c and C57BL/6 mice (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>) together with modified SARS-CoV-2 strains. Modification of the virus has led to mouse-adapted SARS-CoV-2 strains, the SARS-CoV-2 MA (<xref rid="B88" ref-type="bibr">88</xref>) and SARS-CoV-2 MASCp6 (<xref rid="B87" ref-type="bibr">87</xref>) strains, which are able to infect mice with no need for modification of the animals, as these strains efficiently bind to the murine ACE2 receptor in both young and aged mice, causing a disease resembling human COVID-19. In addition to their use in the study of pathogenesis, these models have enabled researchers to trial vaccines and treatments for the disease (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>).</p></sec><sec id="S4.SS6"><title>Mouse Models for the Induction of Neutralizing Antibodies</title><p>BALB/c mice have been used in studies for the development of vaccines, and Wistar rats have been used in studies into immunization with attenuated strains of the virus (<xref rid="B89" ref-type="bibr">89</xref>).</p></sec><sec id="S4.SS7"><title>Syrian Hamster Models</title><p>This animal model (<italic>M. auratus</italic>) has previously been used in the study of SARS-CoV (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>), as the hamster presents an ACE2 receptor homologous to the human receptor. Sia et al. (<xref rid="B92" ref-type="bibr">92</xref>) intranasally inoculated animals with the &#x003b2;&#x02013;CoV/Hong Kong/VM20001061/2020 strain and corroborated the presence of viral antigen in the epithelial cells of the nasal and bronchial mucosa with progression to pneumocytes and clearance of infectious particles by day 7 after infection. Presence of mononuclear cell infiltrates was moderate in the nasal turbinates but was greater in the lungs. The viral antigen was observed in epithelial cells of the duodenum, without signs of inflammation. No infectious particles were detected in the kidney, and no histopathological changes were observed in other organs. Neutralizing antibodies were observed on day 14 after infection. Infected animals presented clear weight loss and researchers corroborated that the main route of viral transmission was through direct contact or aerosols. The authors conclude that SARS-CoV-2 infection in Syrian hamsters presents similar characteristics to those observed in humans with mild infections and that this model represents an opportunity for understanding the transmission dynamics of this novel coronavirus.</p><p>Chan et al. (<xref rid="B93" ref-type="bibr">93</xref>) confirmed transmission by contact, the progressive decrease in viral load between days 2 and 7 after infection in both lower and upper respiratory tracts, and the expression of viral antigens (protein N) by epithelial cells together with presence of mononuclear infiltrates. On day 7 after infection, regenerative hyperplasia occurring in bronchioles led to the appearance of multiple irregularly arranged epithelial layers. Furthermore, they detected the viral antigen in the intestinal mucosa and observed histopathological changes in the spleen and heart. The pro-inflammatory cytokine cascade in this model normalizes at approximately day 7, and antibodies are observed at 7&#x02013;14 days. This animal model reproduces the respiratory and enteric symptoms observed in patients with COVID-19.</p></sec><sec id="S4.SS8"><title>Ferret Models</title><p>Ferrets (<italic>Mustela putorius furo</italic>) are frequently used as animal models to study respiratory diseases caused by such viruses as influenza virus or SARS-CoV (<xref rid="B94" ref-type="bibr">94</xref>&#x02013;<xref rid="B96" ref-type="bibr">96</xref>). All studies with SARS-CoV-2 in ferrets have used the intranasal route to inoculate the virus (<xref rid="B97" ref-type="bibr">97</xref>&#x02013;<xref rid="B99" ref-type="bibr">99</xref>). Shi et al. (<xref rid="B97" ref-type="bibr">97</xref>) studied the susceptibility of ferrets to infection with 2 SARS-CoV-2 strains. In a first stage of the study, the authors detected viral RNA in samples from the nasal turbinates, palate, and tonsils, but no viral load was detected in the other organs analyzed, including the lungs and brain. This suggests that the virus can replicate in the upper respiratory tract of ferrets. In a second stage of the study, analyzing the viral replication dynamics, animals showed viral RNA in nasal washes, whereas rectal swabs showed much lower viral load. Furthermore, ferrets presented anti-SARS-CoV-2 antibodies at days 13 and 20. Histopathological studies showed altered pneumocytes, macrophages, and neutrophils. Finally, when studying replication in the lungs, the authors observed that the virus is able to replicate in the upper respiratory tract up to day 8 after infection without causing severe symptoms. Richard et al. (<xref rid="B98" ref-type="bibr">98</xref>) focused on the study of the direct and indirect transmission of the SARS-CoV-2. Ferrets inoculated with SARS-CoV-2 were placed in direct contact with a group of healthy ferrets 6 h after infection. Inoculated animals showed productive infection, and the peak of viral infection was reached on the third day. All animals in direct or indirect contact presented viral RNA at day 1&#x02013;3 after exposure. Animals exposed to inoculated ferrets were expected to present a lower viral load than the inoculated animals; however, viral load was similar in all cases. Lastly, the authors observed that all animals presented antibodies at day 21 after exposure to the virus, and that their levels were similar, regardless of the form of infection. A similar design was employed by Kim et al. (<xref rid="B99" ref-type="bibr">99</xref>), who observed viral load up to 8 days after infection, both in samples from inoculated animals and in samples from animals that were in direct contact with the inoculated ferrets. Animals in indirect contact with infected ferrets showed positive results for infection at day 2 after exposure, which suggests rapid transmission, even before peak viral load was reached and in the absence of clinical symptoms; this correlates with the reported transmission by asymptomatic human patients.</p></sec><sec id="S4.SS9"><title>Non-human Primate Models</title><p>Severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus have previously been studied in non-human primates (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B100" ref-type="bibr">100</xref>&#x02013;<xref rid="B104" ref-type="bibr">104</xref>); the use of these models has been proposed for the study of SARS-CoV-2 (<xref rid="B105" ref-type="bibr">105</xref>) especially with a view to the development of vaccines or antiviral treatments (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>). Rockx et al. (<xref rid="B105" ref-type="bibr">105</xref>) used a combined intratracheal and intranasal route to inoculate the SARS-CoV-2 virus to both young and old adult cynomolgus macaques (<italic>Macaca fascicularis</italic>). The results of this study showed that these animals tolerated viral infection, presenting symptoms similar to those of COVID-19 in humans. The virus efficiently replicates in epithelial cells throughout the upper respiratory tract, which correlates with the ease of transmission of the virus, whereas replication in the lower respiratory tract correlates with the development of the disease (<xref rid="B105" ref-type="bibr">105</xref>&#x02013;<xref rid="B108" ref-type="bibr">108</xref>). Yu et al. (<xref rid="B100" ref-type="bibr">100</xref>) obtained similar results with intratracheal inoculation of young and old rhesus monkeys (<italic>Macaca mulatta</italic>). The authors report that, although viral replication was more active in older adult monkeys, both groups developed interstitial pneumonia together with edema, which was more severe and diffuse in older adult monkeys. Munster et al. (<xref rid="B105" ref-type="bibr">105</xref>) developed a COVID-19 model using rhesus monkeys, inoculating them with the virus through four different but combined routes (intranasal, intratracheal, conjunctival, and oral). The animals presented clinical signs compatible with COVID-19 from day 1 after the inoculation to symptom resolution, between days 9 and 17. All animals presented weight loss, low-grade fever, and pulmonary infiltrates, in addition to a significant increase in IL-6 and IL-10, among other findings; IgG antibodies were present at detectable levels from day 7 after the infection. Nasal, pharyngeal, and rectal samples showed high levels of viral RNA. Furthermore, histopathological analyses showed similar alterations to those caused by SARS-CoV and MERS-CoV (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Deng et al. (<xref rid="B109" ref-type="bibr">109</xref>) inoculated rhesus monkeys with SARS-CoV-2 through the conjunctival route. They did not observe significant changes in the animals&#x02019; weight or body temperature. Antibody analyses detected presence of IgG at days 14 and 21. Furthermore, radiographs of these animals showed bilateral alterations in the upper lobes and right lower lobe, which correlates with the moderate interstitial pneumonia observed microscopically. Histopathological studies showed viral load in the ocular and nasolacrimal system, as well as in the respiratory and digestive tracts. Results of a comparative study of three non-human primate species [rhesus monkey, crab-eating macaque, and common marmoset (<italic>Callithrix jacchus</italic>)], which were inoculated with the virus through three different pathways (intratracheal, intranasal, and conjunctival), showed that almost all animals presented clinical signs compatible with COVID-19, although there were differences between species in the histopathological findings (<xref rid="B107" ref-type="bibr">107</xref>). The rhesus monkey is the most susceptible species to viral infection, and therefore a good model for the study of COVID-19, as well as for the development of vaccines and pharmacological studies (<xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B108" ref-type="bibr">108</xref>). De Wit et al. (<xref rid="B110" ref-type="bibr">110</xref>) studied rhesus monkeys intratracheally inoculated with the virus, finding that viral RNA was detectable in the throat during the first days, but with levels subsequently decreasing until becoming undetectable. Bao et al. (<xref rid="B111" ref-type="bibr">111</xref>) and Chandrashekar et al. (<xref rid="B112" ref-type="bibr">112</xref>) intratracheally and intranasally inoculated rhesus monkeys with the SARS-CoV-2 virus to study the possibility of reinfection. Williamson et al. (<xref rid="B113" ref-type="bibr">113</xref>) used rhesus monkeys that had previously been inoculated through the intranasal, oral, ocular, and intratracheal routes for pharmacological research. These animals have also been used for the development of vaccines (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>).</p></sec></sec><sec id="S5"><title>Models for CNS Research</title><p>Coronaviruses have been found in autopsy studies in the CNS of patients with multiple sclerosis, Parkinson&#x02019;s disease, and Alzheimer disease. Experimental studies have shown that human CoVs can infect neurons, astrocytes, and microglia in primary cultures as well as immortalized human microglial cells (<xref rid="B6" ref-type="bibr">6</xref>). The suggestion that SARS-CoV-2 may use the brain as a reservoir (<xref rid="B10" ref-type="bibr">10</xref>), potentially favoring the development of neurodegenerative diseases (<xref rid="B11" ref-type="bibr">11</xref>), underscores the need to specifically analyze the effect of the virus on the CNS.</p></sec><sec id="S6"><title>CNS Cell Lines</title><p>The information currently available is from research on SARS-CoV, which has 78% nucleotide homology with SARS-CoV-2 (<xref rid="B18" ref-type="bibr">18</xref>). Although CNS tropism has been described (<xref rid="B20" ref-type="bibr">20</xref>), no specific models of neural cell lines have been developed for the study of SARS-CoV-2; however, neural progenitor cells (NPCs), neurons and microglia derived from human induced pluripotent stem cells (hIPSCs) have already been used in <italic>in vitro</italic> studies of SARS-CoV-2 viral infection, demonstrating the virus potential to infect CNS cells (<xref rid="B116" ref-type="bibr">116</xref>&#x02013;<xref rid="B118" ref-type="bibr">118</xref>). Previous studies with other neurotropic human coronaviruses showed possible neural cell lines susceptible to infection by SARS-CoV-2 that may be useful in studying the possible mechanisms by which the virus infects the CNS. Studies into neural susceptibility to SARS-CoV infection have used cell lines including HOG, a line derived from a human oligodendroglioma that expresses proteins characteristic of oligodendrocytes and is very widely used in the study of neurons (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>) and the C6 cell line, derived from a glioma induced in Wistar Furth rats exposed to N-nitroso-N-methylurea, which is morphologically similar to glioblastoma multiforme when injected into the brains of neonate rats (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Although both cell lines have been shown to be susceptible to SARS-CoV infection, low levels of viral replication have been observed in comparison with such other susceptible cell lines as Vero E6 or Caco-2 (<xref rid="B123" ref-type="bibr">123</xref>). Other cell lines used to study the virulence of HCoV-229E and HCoV-OC43 in the CNS include human H4 brain neuroglioma cells, the LA-N-5 human neuroblastoma cell line, the CHME-5 human fetal microglia cell line, and the U-373 MG and U-87 MG astrocytic lines derived from a human glioblastoma and an astrocytoma, respectively, among many others (<xref rid="B124" ref-type="bibr">124</xref>&#x02013;<xref rid="B129" ref-type="bibr">129</xref>). Cultures of human primary neurons, astrocytes, oligodendrocytes, and microglia have been used to study these viruses (<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>). All these neural cell lines may be useful in the near future to study SARS-CoV-2.</p></sec><sec id="S7"><title>Brain Organoids as a Model of CNS Infection by SARS-CoV-2</title><p>Organoids are miniaturized, simplified, three-dimensional versions of an organ produced <italic>in vitro</italic>, partially recreating the cellular structure and the functioning of that organ (<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>). Classic cell culture systems present certain limitations, such as the inability to study complex and dynamic responses or cell-cell interactions. The use of organoids enables us to study complex physiological or pathological processes in structures bearing much greater resemblance to <italic>in vivo</italic> conditions, including SARS-CoV-2 infection, tropisms and potential treatments (<xref rid="B133" ref-type="bibr">133</xref>&#x02013;<xref rid="B135" ref-type="bibr">135</xref>). To date, SARS-CoV-2 infection has been studied in human organoids of lung, liver, intestine, blood vessels, and kidney (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B136" ref-type="bibr">136</xref>&#x02013;<xref rid="B138" ref-type="bibr">138</xref>). Human brain organoids have also been used; these present strong cellular and structural similarities to some mammalian brain regions, such as a neural epithelium containing NPCs, that align to form a ventricular zone-like layer, cortical neurons, that contribute to the formation of a cortical plate-like layer and glial cells, such as astrocytes or oligodendrocytes (<xref rid="B139" ref-type="bibr">139</xref>&#x02013;<xref rid="B141" ref-type="bibr">141</xref>). These organoids are useful for the study of early stages of human neurodevelopment and network formation, key cellular processes such as proliferation, differentiation, apoptosis, synaptogenesis or myelination, CNS function such as electrophysiological activity, neurodegenerative diseases, potential treatments, and have been already used for the study of other virus such as ZIKA virus or HIV (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B141" ref-type="bibr">141</xref>&#x02013;<xref rid="B144" ref-type="bibr">144</xref>).</p><p>Ramani et al. (<xref rid="B116" ref-type="bibr">116</xref>) observed that in these brain organoids, the virus mainly infects mature cortical neurons and presents a perinuclear distribution within these cells. Furthermore, neurodegenerative effects have been observed in cells infected by SARS-CoV-2, including cell death and hyperphosphorylation, as well as mislocation of Tau protein; these alterations are observed in such conditions as tauopathies or Alzheimer disease (<xref rid="B116" ref-type="bibr">116</xref>). However, no productive replication of the virus was observed in these cells, at least in the first 4 days after infection (<xref rid="B116" ref-type="bibr">116</xref>), which would support the hypothesis that the CNS may act as a long-term reservoir of the virus (<xref rid="B10" ref-type="bibr">10</xref>). In contrast, Bullen et al. (<xref rid="B139" ref-type="bibr">139</xref>) observed an incremented accumulation of viral particles in neural cells of brain organoids between 6 and 72 h after SARS-CoV-2 infection, suggesting an active replication and productive infection of the virus in neural cells during the first days. Viral particles were detected mainly in the neuronal soma and, in some cells, also into the neurites (<xref rid="B139" ref-type="bibr">139</xref>). Similar to Ramani et al., Mesci et al. (<xref rid="B141" ref-type="bibr">141</xref>) used these brain organoids and observed that the virus was able to infect neurons, including NPCs and mature cortical neurons, and cause cell death accompanied by the impairment of excitatory synapses. Furthermore, this work tested the efficiency of Sofosbuvir, an FDA-approved brain-penetrant antiviral drug for positive-sense single-stranded RNA viruses (<xref rid="B145" ref-type="bibr">145</xref>), as a treatment for the SARS-CoV-2 infection and observed that this drug was able to rescue the altered synaptogenesis and decrease neuronal death and viral accumulation in these brain organoids (<xref rid="B141" ref-type="bibr">141</xref>). Song et al. (<xref rid="B117" ref-type="bibr">117</xref>) also demonstrated that SARS-CoV-2 has neuroinvasive capacity in human brain organoids, particularly of NPCs and mature cortical neurons. Infected cells showed a hypermetabolic state and viral particles were accumulated within endoplasmic reticulum-like structures, indicating the virus ability to use the neural cell machinery to replicate (<xref rid="B117" ref-type="bibr">117</xref>). In addition, a hypoxic environment and extensive neuronal cell death were observed in high density SARS-CoV-2 infected areas, suggesting that virus infection could promote death of nearby cells (<xref rid="B117" ref-type="bibr">117</xref>). Finally, this study detected IgG antibodies against SARS-CoV-2 in the cerebrospinal fluid of a COVID-19 patient that were able to block SARS-CoV-2 infection in brain organoids (<xref rid="B117" ref-type="bibr">117</xref>). All these studies show that SARS-CoV-2 can directly infect neural cells and trigger damaging consequences that could cause neurologic symptoms. Also, these studies expose the great potential of the human brain organoids for the study of the SARS-CoV-2 effects in the CNS.</p></sec><sec id="S8"><title>MHV-CoV Infection in Mice</title><p>Mouse hepatitis virus (MHV) is a &#x003b2;CoV that poses no risk to humans but presents a great similarity with other viruses from the same family, such as SARS-CoV, MERS-CoV, and SARS-CoV-2. It penetrates the CNS, causing white matter lesions; it has therefore been proposed as a viral model of demyelinating disease (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>). The virus has been shown to remain in the white matter and to be able to replicate in the CNS (<xref rid="B148" ref-type="bibr">148</xref>); therefore, it is a good model for the study of CNS infection by coronaviruses. Neurotropic strains of MHV-CoV have been used extensively to induce acute and chronic demyelinating disease mediated by neuroinflammation (<xref rid="B149" ref-type="bibr">149</xref>). Depending on the inoculation route and the MHV-CoV strain, different CNS regions are affected. Inoculation with experimental neurotropic strains, especially MHV-A59, induces a biphasic disease of acute meningoencephalitis at 10&#x02013;14 days after inoculation, followed by a disease causing subacute, chronic inflammatory demyelination in the brain; spinal cord involvement is more pronounced (<xref rid="B150" ref-type="bibr">150</xref>). Virus translocation from the initial site of inoculation in the brain to the spinal cord is caused by the transit of virus particles in neural and glial cells, as well as mechanisms that involve the fusion of lipid membranes, probably during the virus internalization step (<xref rid="B151" ref-type="bibr">151</xref>). Intranasal and intracranial inoculation of JHM-CoV induces similar symptoms in BALB/c mice to those caused by MHV-A59. After intranasal inoculation of mice, MHV-CoV accesses the CNS through the olfactory nerve and propagates from the olfactory system to limbic system structures and their connections with the brainstem (<xref rid="B152" ref-type="bibr">152</xref>).</p><p>In order to study the immune system role in demyelination induction caused by MHV infection, Wang et al. (<xref rid="B153" ref-type="bibr">153</xref>) treated infected animals with gamma radiation to cause immunosuppression and, subsequently, reconstituted immunity by transferring cells from other immunocompetent animals. The results showed that demyelination was prevented by radiation and was present again when the immunity was restored, indicating that immunity is directly involved in the demyelination process (<xref rid="B153" ref-type="bibr">153</xref>). Moreover, CD4 and CD8 T cells have been observed to play a critical role in the development of the demyelinating process, with &#x003b3;&#x003b4; T cells being the most important for this process (<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>). In contrast, B cells, the most abundant cell type in the spleen, and NK cells are not involved in demyelination as nude animals without spleen do not present demyelination (<xref rid="B154" ref-type="bibr">154</xref>), MHV offers a unique model for studying host defense-mediated demyelination during chronic infection in a phase acute viral infection and immune response (<xref rid="B156" ref-type="bibr">156</xref>).</p></sec><sec id="S9"><title>Conclusion</title><p>Research on SARS-CoV-2 has become a necessity due to the magnitude of its spread worldwide. Such aspects as infection rate and mechanisms, the possibility of reinfection, and possible therapeutic approaches make it necessary not only to use the experimental models previously employed to study the SARS-CoV and MERS-CoV coronaviruses, but also to generate new models to respond to urgent questions. The potential involvement of the CNS due to SARS-CoV-2 infection should be studied specifically, and research efforts must focus on obtaining information with cellular or animal models to expand our understanding of the virus.</p></sec><sec id="S10"><title>Author Contributions</title><p>JM-G and UG-P: lead researchers. All authors: research project group, manuscript drafting, and critical review of the manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>The authors would like to thank the Spanish Society of Neurology&#x02019;s Research Operations Office for assisting with the English-language version of the manuscript.</p></ack><sec id="S12" sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.02163/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.02163/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothan</surname><given-names>HA</given-names></name><name><surname>Byrareddy</surname><given-names>SN.</given-names></name></person-group>
<article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.</article-title>
<source><italic>J Autoimmun.</italic></source> (<year>2020</year>) <volume>109</volume>:<issue>102433</issue>. <pub-id pub-id-type="doi">10.1016/j.jaut.2020.102433</pub-id>
<?supplied-pmid 32113704?><pub-id pub-id-type="pmid">32113704</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>JS</given-names></name><name><surname>Smith</surname><given-names>DW.</given-names></name></person-group>
<article-title>COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don&#x02019;t [published online ahead of print, 2020 Mar 17].</article-title>
<source><italic>Microbiol Aust.</italic></source> (<year>2020</year>) <volume>41</volume>:<issue>MA20013</issue>. <pub-id pub-id-type="doi">10.1071/MA20013</pub-id>
<?supplied-pmid 32226946?><pub-id pub-id-type="pmid">32226946</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>On the origin and continuing evolution of SARS-CoV-2.</article-title>
<source><italic>Natl Sci Rev.</italic></source> (<year>2020</year>) <volume>2020</volume>:<fpage>1012</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/nsr/nwaa036</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>P</given-names></name><name><surname>Forster</surname><given-names>L</given-names></name><name><surname>Renfrew</surname><given-names>C</given-names></name><name><surname>Forster</surname><given-names>M.</given-names></name></person-group>
<article-title>Phylogenetic network analysis of SARS-CoV-2 genomes.</article-title>
<source><italic>Proc Natl Acad Sci USA.</italic></source> (<year>2020</year>) <volume>117</volume>:<fpage>9241</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2004999117</pub-id>
<?supplied-pmid 32269081?><pub-id pub-id-type="pmid">32269081</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>LJ</given-names></name><name><surname>Paula de Lima Gusm&#x000e3;o</surname><given-names>T</given-names></name><name><surname>Machado</surname><given-names>ZA</given-names></name><name><surname>Leao</surname><given-names>FJ</given-names></name><name><surname>Barkokebas Santos de Faria</surname><given-names>A</given-names></name><name><surname>Morais</surname><given-names>SIH</given-names></name><etal/></person-group>
<article-title>Coronaviridae - old friends, new enemy!</article-title>
<source><italic>Oral Dis.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1111/odi.13447</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32475006?><pub-id pub-id-type="pmid">32475006</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabaan</surname><given-names>AA</given-names></name><name><surname>Al-Ahmed</surname><given-names>SH</given-names></name><name><surname>Haque</surname><given-names>S</given-names></name><name><surname>Sah</surname><given-names>R</given-names></name><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Malik</surname><given-names>YS</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview.</article-title>
<source><italic>Infez Med.</italic></source> (<year>2020</year>) <volume>28</volume>:<fpage>174</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32275259</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mat&#x000ed;as-Guiu</surname><given-names>J</given-names></name><name><surname>Gomez-Pinedo</surname><given-names>U</given-names></name><name><surname>Montero-Escribano</surname><given-names>P</given-names></name><name><surname>Gomez-Iglesias</surname><given-names>P</given-names></name><name><surname>Porta-Etessam</surname><given-names>J</given-names></name><name><surname>Matias-Guiu</surname><given-names>JA.</given-names></name></person-group>
<article-title>?&#x02018;Es esperable que haya cuadros neurol&#x000f3;gicos por la pandemia por SARS-CoV-2?</article-title>
<source><italic>Neurologia.</italic></source> (<year>2020</year>) <volume>35</volume>:<fpage>170</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.nrl.2020.03.001</pub-id>
<?supplied-pmid 32299636?><pub-id pub-id-type="pmid">32299636</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paniz-Mondolfi</surname><given-names>A</given-names></name><name><surname>Bryce</surname><given-names>C</given-names></name><name><surname>Grimes</surname><given-names>Z</given-names></name><name><surname>Gordon</surname><given-names>RE</given-names></name><name><surname>Reidy</surname><given-names>J</given-names></name><name><surname>Lednicky</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Central nervous system involvement by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2).</article-title>
<source><italic>J Med Virol.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/jmv.25915</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32314810?><pub-id pub-id-type="pmid">32314810</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulfamante</surname><given-names>G</given-names></name><name><surname>Chiumello</surname><given-names>D</given-names></name><name><surname>Canevini</surname><given-names>MP</given-names></name><name><surname>Priori</surname><given-names>A</given-names></name><name><surname>Mazzanti</surname><given-names>M</given-names></name><name><surname>Centanni</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>First ultrastructural autoptic findings of SARS-Cov-2 in olfactory pathways and brainstem.</article-title>
<source><italic>Minerva Anestesiol.</italic></source> (<year>2020</year>): <pub-id pub-id-type="doi">10.23736/S0375-9393.20.14772-2</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32401000?><pub-id pub-id-type="pmid">32401000</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Pinedo</surname><given-names>U</given-names></name><name><surname>Matias-Guiu</surname><given-names>J</given-names></name><name><surname>Sanclemente-Alaman</surname><given-names>I</given-names></name><name><surname>Moreno-Jimenez</surname><given-names>L</given-names></name><name><surname>Montero-Escribano</surname><given-names>P</given-names></name><name><surname>Matias-Guiu</surname><given-names>JA.</given-names></name></person-group>
<article-title>Is the brain a reservoir organ for SARS-CoV2?</article-title>
<source><italic>J Med Virol.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/jmv.26046</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32437002?><pub-id pub-id-type="pmid">32437002</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Pinedo</surname><given-names>U</given-names></name><name><surname>Matias-Guiu</surname><given-names>J</given-names></name><name><surname>Sanclemente-Alaman</surname><given-names>I</given-names></name><name><surname>Moreno-Jimenez</surname><given-names>L</given-names></name><name><surname>Montero-Escribano</surname><given-names>P</given-names></name><name><surname>Matias-Guiu</surname><given-names>JA.</given-names></name></person-group>
<article-title>SARS-CoV2 as a potential trigger of neurodegenerative diseases.</article-title>
<source><italic>Mov Disord.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/mds.28179</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32502296?><pub-id pub-id-type="pmid">32502296</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group>
<article-title>Infectivity of human coronavirus in the brain [published online ahead of print, 2020 May 28].</article-title>
<source><italic>EBioMedicine.</italic></source> (<year>2020</year>) <volume>56</volume>:<issue>102799</issue>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102799</pub-id>
<?supplied-pmid 32474399?><pub-id pub-id-type="pmid">32474399</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinzon</surname><given-names>RT</given-names></name><name><surname>Wijaya</surname><given-names>VO</given-names></name><name><surname>Buana</surname><given-names>RB</given-names></name><name><surname>Al Jody</surname><given-names>A</given-names></name><name><surname>Nunsio</surname><given-names>PN.</given-names></name></person-group>
<article-title>Neurologic Characteristics in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.</article-title>
<source><italic>Front Neurol.</italic></source> (<year>2020</year>) <volume>11</volume>:<issue>565</issue>. <pub-id pub-id-type="doi">10.3389/fneur.2020.00565</pub-id>
<?supplied-pmid 32574250?><pub-id pub-id-type="pmid">32574250</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiani</surname><given-names>B</given-names></name><name><surname>Covarrubias</surname><given-names>C</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Sekhon</surname><given-names>M</given-names></name><name><surname>Jarrah</surname><given-names>RA.</given-names></name></person-group>
<article-title>Contemporary Review of Neurological Sequelae of COVID-19.</article-title>
<source><italic>Front Neurol.</italic></source> (<year>2020</year>) <volume>11</volume>:<issue>640</issue>. <pub-id pub-id-type="doi">10.3389/fneur.2020.00640</pub-id>
<?supplied-pmid 32655489?><pub-id pub-id-type="pmid">32655489</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name></person-group>
<article-title>Potential of SARS-CoV-2 to cause CNS infection: biologic fundamental and clinical experience.</article-title>
<source><italic>Front Neurol.</italic></source> (<year>2020</year>) <volume>11</volume>:<issue>659</issue>. <pub-id pub-id-type="doi">10.3389/fneur.2020.00659</pub-id>
<?supplied-pmid 32625165?><pub-id pub-id-type="pmid">32625165</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre-Fuentes</surname><given-names>L</given-names></name><name><surname>Mat&#x000ed;as-Guiu</surname><given-names>J</given-names></name><name><surname>Hern&#x000e1;ndez-Lorenzo</surname><given-names>L</given-names></name><name><surname>Montero-Escribano</surname><given-names>P</given-names></name><name><surname>Pytel</surname><given-names>V</given-names></name><name><surname>Porta-Etessam</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.</article-title>
<source><italic>J Med Virol.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/jmv.26319</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32691890?><pub-id pub-id-type="pmid">32691890</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Iglesias</surname><given-names>P</given-names></name><name><surname>Porta-Etessam</surname><given-names>J</given-names></name><name><surname>Montalvo</surname><given-names>T</given-names></name><name><surname>Valls-Carb&#x000f3;</surname><given-names>A</given-names></name><name><surname>Gajate</surname><given-names>V</given-names></name><name><surname>Mat&#x000ed;as-Guiu</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>An online observational study of patients with olfactory and gustory alterations secondary to SARS-CoV-2 infection.</article-title>
<source><italic>Front Public Health.</italic></source> (<year>2020</year>) <volume>8</volume>:<issue>243</issue>. <pub-id pub-id-type="doi">10.3389/fpubh.2020.00243</pub-id>
<?supplied-pmid 32574308?><pub-id pub-id-type="pmid">32574308</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group>
<article-title>Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus.</article-title>
<source><italic>J Virol.</italic></source> (<year>2020</year>) <volume>94</volume>:<issue>e00127-20</issue>. <pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id>
<?supplied-pmid 31996437?><pub-id pub-id-type="pmid">31996437</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukassen</surname><given-names>S</given-names></name><name><surname>Chua</surname><given-names>RL</given-names></name><name><surname>Trefzer</surname><given-names>T</given-names></name><name><surname>Kahn</surname><given-names>NC</given-names></name><name><surname>Schneider</surname><given-names>MA</given-names></name><name><surname>Muley</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.</article-title>
<source><italic>EMBO J.</italic></source> (<year>2020</year>) <volume>39</volume>:<issue>e105114</issue>. <pub-id pub-id-type="doi">10.15252/embj.20105114</pub-id>
<?supplied-pmid 32246845?><pub-id pub-id-type="pmid">32246845</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>From SARS to MERS, thrusting coronaviruses into the spotlight.</article-title>
<source><italic>Viruses.</italic></source> (<year>2019</year>) <volume>11</volume>:<issue>59</issue>. <pub-id pub-id-type="doi">10.3390/v11010059</pub-id>
<?supplied-pmid 30646565?><pub-id pub-id-type="pmid">30646565</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>AM</given-names></name><name><surname>Khaleeq</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>U</given-names></name><name><surname>Syeda</surname><given-names>H.</given-names></name></person-group>
<article-title>Evidence of the COVID-19 Virus Targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms.</article-title>
<source><italic>ACS Chem Neurosci.</italic></source> (<year>2020</year>) <volume>11</volume>:<fpage>995</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.0c00122</pub-id>
<?supplied-pmid 32167747?><pub-id pub-id-type="pmid">32167747</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin.</article-title>
<source><italic>Nature.</italic></source> (<year>2020</year>) <volume>579</volume>:<fpage>270</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<?supplied-pmid 32015507?><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.</article-title>
<source><italic>Cell.</italic></source> (<year>2020</year>) <volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>80.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
<?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Chong</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name></person-group>
<article-title>Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity.</article-title>
<source><italic>J Virol.</italic></source> (<year>2020</year>) <volume>94</volume>:<issue>e00635-20</issue>. <pub-id pub-id-type="doi">10.1128/JVI.00635-20</pub-id>
<?supplied-pmid 32376627?><pub-id pub-id-type="pmid">32376627</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Canard</surname><given-names>B</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name></person-group>
<article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.</article-title>
<source><italic>Antiviral Res.</italic></source> (<year>2020</year>) <volume>176</volume>:<issue>104742</issue>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104742</pub-id>
<?supplied-pmid 32057769?><pub-id pub-id-type="pmid">32057769</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.</article-title>
<source><italic>Cell Res.</italic></source> (<year>2020</year>) <volume>30</volume>:<fpage>343</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>
<?supplied-pmid 32231345?><pub-id pub-id-type="pmid">32231345</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Choi</surname><given-names>GK</given-names></name><name><surname>To</surname><given-names>KW</given-names></name><name><surname>Tse</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: Implications for disease pathogenesis and clinical manifestation.</article-title>
<source><italic>Infest Dis.</italic></source> (<year>2013</year>) <volume>207</volume>:<fpage>1743</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit123</pub-id>
<?supplied-pmid 23532101?><pub-id pub-id-type="pmid">23532101</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swearengen</surname><given-names>JR.</given-names></name></person-group>
<article-title>Choosing the right animal model for infectious disease research.</article-title>
<source><italic>Animal Model Exp Med.</italic></source> (<year>2018</year>) <volume>1</volume>:<fpage>100</fpage>&#x02013;<lpage>08</lpage>. <pub-id pub-id-type="doi">10.1002/ame2.12020</pub-id>
<?supplied-pmid 30891554?><pub-id pub-id-type="pmid">30891554</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Shih</surname><given-names>TP</given-names></name><name><surname>Ko</surname><given-names>WC</given-names></name><name><surname>Tang</surname><given-names>HJ</given-names></name><name><surname>Hsueh</surname><given-names>PR.</given-names></name></person-group>
<article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.</article-title>
<source><italic>Int J Antimicrob Agents.</italic></source> (<year>2020</year>) <volume>55</volume>:<issue>105924</issue>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105924</pub-id>
<?supplied-pmid 32081636?><pub-id pub-id-type="pmid">32081636</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group>
<article-title>Proteomic analysis of membrane proteins of vero cells: exploration of potential proteins responsible for virus entry.</article-title>
<source><italic>DNA Cell Biol.</italic></source> (<year>2014</year>) <volume>33</volume>:<fpage>20</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/dna.2013.2193</pub-id>
<?supplied-pmid 24286161?><pub-id pub-id-type="pmid">24286161</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Berneet</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.</article-title>
<source><italic>Nature.</italic></source> (<year>2003</year>) <volume>426</volume>:<fpage>450</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id>
<?supplied-pmid 14647384?><pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>ML</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>See</surname><given-names>EE</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Ling</surname><given-names>AE.</given-names></name></person-group>
<article-title>Early events of SARS coronavirus infection in vero cells.</article-title>
<source><italic>J Med Virol.</italic></source> (<year>2003</year>) <volume>71</volume>:<fpage>323</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.10499</pub-id>
<?supplied-pmid 12966536?><pub-id pub-id-type="pmid">12966536</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamate</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>YG</given-names></name><name><surname>Warachit</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Establishment of vero E6 cell clones persistently infected with severe acute respiratory syndrome coronavirus.</article-title>
<source><italic>Microbes Infect.</italic></source> (<year>2005</year>) <volume>7</volume>:<fpage>1530</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2005.05.013</pub-id>
<?supplied-pmid 16269264?><pub-id pub-id-type="pmid">16269264</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaye</surname><given-names>M.</given-names></name></person-group>
<article-title>SARS-associated coronavirus replication in cell lines.</article-title>
<source><italic>Emerg Infect Dis.</italic></source> (<year>2006</year>) <volume>12</volume>:<fpage>128</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.3201/eid1201.050496</pub-id>
<?supplied-pmid 16494729?><pub-id pub-id-type="pmid">16494729</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Ho</surname><given-names>CT</given-names></name><name><surname>Chuo</surname><given-names>WH</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Lin</surname><given-names>CC.</given-names></name></person-group>
<article-title>Effective inhibition of MERS-CoV infection by resveratrol.</article-title>
<source><italic>BMC Infect Dis.</italic></source> (<year>2017</year>) <volume>17</volume>:<issue>144</issue>. <pub-id pub-id-type="doi">10.1186/s12879-017-2253-8</pub-id>
<?supplied-pmid 28193191?><pub-id pub-id-type="pmid">28193191</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudeep</surname><given-names>AB</given-names></name><name><surname>Vyas</surname><given-names>PB</given-names></name><name><surname>Parashar</surname><given-names>D</given-names></name><name><surname>Shil</surname><given-names>P.</given-names></name></person-group>
<article-title>Differential susceptibility &#x00026; replication potential of Vero E6, BHK-21, RD, A-549, C6/36 cells &#x00026; Aedes aegypti mosquitoes to three strains of chikungunya virus.</article-title>
<source><italic>Indian J Med Res.</italic></source> (<year>2019</year>) <volume>149</volume>:<fpage>771</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.IJMR_453_17</pub-id><pub-id pub-id-type="pmid">31496530</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>PN</given-names></name><name><surname>Mundt</surname><given-names>W</given-names></name><name><surname>Kistner</surname><given-names>O</given-names></name><name><surname>Howard</surname><given-names>MK.</given-names></name></person-group>
<article-title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.</article-title>
<source><italic>Expert Rev Vaccines.</italic></source> (<year>2009</year>) <volume>8</volume>:<fpage>607</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.19</pub-id>
<?supplied-pmid 19397417?><pub-id pub-id-type="pmid">19397417</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Chang</surname><given-names>JK</given-names></name><name><surname>Tang</surname><given-names>RB.</given-names></name></person-group>
<article-title>Current recommendations for the Japanese encephalitis vaccine.</article-title>
<source><italic>J Chin Med Assoc.</italic></source> (<year>2015</year>) <volume>78</volume>:<fpage>271</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcma.2014.12.009</pub-id>
<?supplied-pmid 25841620?><pub-id pub-id-type="pmid">25841620</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.</article-title>
<source><italic>Nat Commun.</italic></source> (<year>2020</year>) <volume>11</volume>:<issue>1620</issue>. <pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id>
<?supplied-pmid 32221306?><pub-id pub-id-type="pmid">32221306</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.03.14.988345</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WD</given-names></name><name><surname>Chang</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Tsai</surname><given-names>MJ</given-names></name><name><surname>Hung</surname><given-names>CC</given-names></name><name><surname>Hsuet</surname><given-names>CL</given-names></name><etal/></person-group>
<article-title>Prolonged virus shedding even after seroconversion in a patient with COVID-19.</article-title>
<source><italic>J Infect.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.063</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32283147?><pub-id pub-id-type="pmid">32283147</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chiu</surname><given-names>MC</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Infection of bat and human intestinal organoids by SARS-CoV-2.</article-title>
<source><italic>Nat Med.</italic></source> (<year>2020</year>) <volume>26</volume>:<fpage>1077</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0912-6</pub-id>
<?supplied-pmid 32405028?><pub-id pub-id-type="pmid">32405028</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Baudoin</surname><given-names>JP</given-names></name><name><surname>Bou Khalil</surname><given-names>J</given-names></name><name><surname>La Scola</surname><given-names>B</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group>
<article-title>Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2.</article-title>
<source><italic>Eur J Clin Microbiol Infect Dis.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1007/s10096-020-03869-w</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32270412?><pub-id pub-id-type="pmid">32270412</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM.</given-names></name></person-group>
<article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [published online ahead of print, 2020 Apr 3].</article-title>
<source><italic>Antiviral Res.</italic></source> (<year>2020</year>) <volume>178</volume>:<issue>104787</issue>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id>
<?supplied-pmid 32251768?><pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.</article-title>
<source><italic>Cell Discov.</italic></source> (<year>2020</year>) <volume>6</volume>:<issue>16</issue>. <pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id>
<?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</article-title>
<source><italic>Cell Res.</italic></source> (<year>2020</year>) <volume>30</volume>:<fpage>269</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
<?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 Mar 9].</article-title>
<source><italic>Clin Infect Dis.</italic></source> (<year>2020</year>) <volume>71</volume>:<issue>ciaa237</issue>. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id>
<?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runfeng</surname><given-names>L</given-names></name><name><surname>Yunlong</surname><given-names>H</given-names></name><name><surname>Jicheng</surname><given-names>H</given-names></name><name><surname>Weiqi</surname><given-names>P</given-names></name><name><surname>Qinhai</surname><given-names>M</given-names></name><name><surname>Yongxiaet</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).</article-title>
<source><italic>Pharmacol Res.</italic></source> (<year>2020</year>) <volume>156</volume>:<issue>104761</issue>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104761</pub-id>
<?supplied-pmid 32205232?><pub-id pub-id-type="pmid">32205232</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanenko</surname><given-names>AA</given-names></name><name><surname>Dmitrenko</surname><given-names>VV.</given-names></name></person-group>
<article-title>HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution.</article-title>
<source><italic>Gene.</italic></source> (<year>2015</year>) <volume>569</volume>:<fpage>182</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2015.05.065</pub-id>
<?supplied-pmid 26026906?><pub-id pub-id-type="pmid">26026906</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Analysis of circular RNA expression profile in HEK 293T cells exposed to ionizing radiation.</article-title>
<source><italic>Dose Response.</italic></source> (<year>2019</year>) <volume>17</volume>:<issue>1559325819837795</issue>. <pub-id pub-id-type="doi">10.1177/1559325819837795</pub-id>
<?supplied-pmid 31040759?><pub-id pub-id-type="pmid">31040759</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Nathan</surname><given-names>L</given-names></name><name><surname>Jaimes</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>H</given-names></name><name><surname>Dan</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting.</article-title>
<source><italic>J Vis Exp.</italic></source> (<year>2019</year>) <volume>1</volume>:<issue>145</issue>. <pub-id pub-id-type="doi">10.3791/59010</pub-id>
<?supplied-pmid 30882796?><pub-id pub-id-type="pmid">30882796</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Shang</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>A subcellular quantitative proteomic analysis of herpes simplex virus type 1-infected HEK 293T Cells.</article-title>
<source><italic>Molecules.</italic></source> (<year>2019</year>) <volume>24</volume>:<issue>4215</issue>. <pub-id pub-id-type="doi">10.3390/molecules24234215</pub-id>
<?supplied-pmid 31757042?><pub-id pub-id-type="pmid">31757042</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>ZF</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name></person-group>
<article-title>Cholesterol 25-hydroxylase suppresses rabies virus infection by inhibiting viral entry.</article-title>
<source><italic>Arch Virol.</italic></source> (<year>2019</year>) <volume>164</volume>:<fpage>2963</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-019-04415-6</pub-id>
<?supplied-pmid 31552533?><pub-id pub-id-type="pmid">31552533</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capstick</surname><given-names>PB</given-names></name><name><surname>Telling</surname><given-names>RC</given-names></name><name><surname>Chapman</surname><given-names>WG</given-names></name><name><surname>Stewart</surname><given-names>DL.</given-names></name></person-group>
<article-title>Growth of a cloned strain of hamster kidney cells in suspended cultures and their susceptibility to the virus of foot-and-mouth disease.</article-title>
<source><italic>Nature.</italic></source> (<year>1962</year>) <volume>195</volume>:<fpage>1163</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/1951163a0</pub-id>
<?supplied-pmid 13876400?><pub-id pub-id-type="pmid">13876400</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>DT.</given-names></name></person-group>
<article-title>Growth and maintenance of baby hamster kidney (BHK) cells.</article-title>
<source><italic>Curr Protoc Microbiol.</italic></source> (<year>2010</year>) <volume>17</volume>:<fpage>A.4H.1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/9780471729259.mca04hs17</pub-id>
<?supplied-pmid 20440683?><pub-id pub-id-type="pmid">20440683</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amadori</surname><given-names>M</given-names></name><name><surname>Volpe</surname><given-names>G</given-names></name><name><surname>Defilippi</surname><given-names>P</given-names></name><name><surname>Berneri</surname><given-names>C.</given-names></name></person-group>
<article-title>Phenotypic features of BHK-21 cells used for production of foot-and-mouth disease vaccine.</article-title>
<source><italic>Biologicals.</italic></source> (<year>1997</year>) <volume>25</volume>:<fpage>65</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1006/biol.1996.0061</pub-id>
<?supplied-pmid 9167010?><pub-id pub-id-type="pmid">9167010</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene.</article-title>
<source><italic>Antimicrob Agents Chemother.</italic></source> (<year>2016</year>) <volume>60</volume>:<fpage>5492</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00814-16</pub-id>
<?supplied-pmid 27381385?><pub-id pub-id-type="pmid">27381385</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasai</surname><given-names>F</given-names></name><name><surname>Hirayama</surname><given-names>N</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Kohara</surname><given-names>A.</given-names></name></person-group>
<article-title>HuH-7 reference genome profile: complex karyotype composed of massive loss of heterozygosity.</article-title>
<source><italic>Hum Cell.</italic></source> (<year>2018</year>) <volume>31</volume>:<fpage>261</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1007/s13577-018-0212-3</pub-id>
<?supplied-pmid 29774518?><pub-id pub-id-type="pmid">29774518</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behnam</surname><given-names>MA</given-names></name><name><surname>Nitsche</surname><given-names>C</given-names></name><name><surname>Boldescu</surname><given-names>V</given-names></name><name><surname>Klein</surname><given-names>CD.</given-names></name></person-group>
<article-title>The Medicinal chemistry of dengue virus.</article-title>
<source><italic>J Med Chem.</italic></source> (<year>2016</year>) <volume>59</volume>:<fpage>5622</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01653</pub-id>
<?supplied-pmid 26771861?><pub-id pub-id-type="pmid">26771861</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciotti</surname><given-names>M</given-names></name><name><surname>Angeletti</surname><given-names>S</given-names></name><name><surname>Minieri</surname><given-names>M</given-names></name><name><surname>Giovannetti</surname><given-names>M</given-names></name><name><surname>Benvenuto</surname><given-names>D</given-names></name><name><surname>Pascarella</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>COVID-19 outbreak: an overview [published online ahead of print, 2020 Apr 7].</article-title>
<source><italic>Chemotherapy.</italic></source> (<year>2020</year>) <volume>64</volume>:<fpage>215</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1159/000507423</pub-id>
<?supplied-pmid 32259829?><pub-id pub-id-type="pmid">32259829</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>VJ</given-names></name><name><surname>Kerr</surname><given-names>HA</given-names></name><name><surname>McQuilkin</surname><given-names>WT</given-names></name><name><surname>Earle</surname><given-names>WR</given-names></name><name><surname>Hull</surname><given-names>RN.</given-names></name></person-group>
<article-title>Growth in vitro of a long-term strain of monkey-kidney cells in medium NCTC 109 free of any added protein.</article-title>
<source><italic>Am J Hyg.</italic></source> (<year>1959</year>) <volume>70</volume>:<fpage>297</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120078</pub-id>
<?supplied-pmid 13821019?><pub-id pub-id-type="pmid">13821019</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>RN</given-names></name><name><surname>Cherry</surname><given-names>WR</given-names></name><name><surname>Tritch</surname><given-names>OJ.</given-names></name></person-group>
<article-title>Growth characteristics of monkey kidney cell strains LLC-MK1, LLC-MK2, and LLC-MK2(NCTC-3196) and their utility in virus research.</article-title>
<source><italic>J Exp Med.</italic></source> (<year>1962</year>) <volume>115</volume>:<fpage>903</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1084/jem.115.5.903</pub-id>
<?supplied-pmid 14449901?><pub-id pub-id-type="pmid">14449901</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milewska</surname><given-names>A</given-names></name><name><surname>Nowak</surname><given-names>P</given-names></name><name><surname>Owczarek</surname><given-names>K</given-names></name><name><surname>Szczepanski</surname><given-names>A</given-names></name><name><surname>Zarebski</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Entry of human coronavirus NL63 into the cell.</article-title>
<source><italic>J Virol.</italic></source> (<year>2018</year>) <volume>92</volume>:<issue>e01933-17</issue>. <pub-id pub-id-type="doi">10.1128/JVI.01933-17</pub-id>
<?supplied-pmid 29142129?><pub-id pub-id-type="pmid">29142129</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>IJ</given-names></name><name><surname>Raub</surname><given-names>TJ</given-names></name><name><surname>Borchardt</surname><given-names>RT.</given-names></name></person-group>
<article-title>Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability.</article-title>
<source><italic>Gastroenterology.</italic></source> (<year>1989</year>) <volume>96</volume>:<fpage>736</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/s0016-5085(89)80072-1</pub-id><pub-id pub-id-type="pmid">2914637</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Breemen</surname><given-names>RB</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group>
<article-title>Caco-2 cell permeability assays to measure drug absorption.</article-title>
<source><italic>Expert Opin Drug Metab Toxicol.</italic></source> (<year>2005</year>) <volume>1</volume>:<fpage>175</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1517/17425255.1.2.175</pub-id>
<?supplied-pmid 16922635?><pub-id pub-id-type="pmid">16922635</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbajo-Lozoya</surname><given-names>J</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Kallies</surname><given-names>S</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>von Brunn</surname><given-names>A.</given-names></name></person-group>
<article-title>Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.</article-title>
<source><italic>Virus Res.</italic></source> (<year>2012</year>) <volume>165</volume>:<fpage>112</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2012.02.002</pub-id>
<?supplied-pmid 22349148?><pub-id pub-id-type="pmid">22349148</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbajo-Lozoya</surname><given-names>J</given-names></name><name><surname>Ma-Lauer</surname><given-names>Y</given-names></name><name><surname>Male&#x00161;evi&#x00107;</surname><given-names>M</given-names></name><name><surname>Theuerkorn</surname><given-names>M</given-names></name><name><surname>Kahlert</surname><given-names>V</given-names></name><name><surname>Prell</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir.</article-title>
<source><italic>Virus Res.</italic></source> (<year>2014</year>) <volume>184</volume>:<fpage>44</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.02.010</pub-id>
<?supplied-pmid 24566223?><pub-id pub-id-type="pmid">24566223</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreft</surname><given-names>ME</given-names></name><name><surname>Jerman</surname><given-names>UD</given-names></name><name><surname>Lasi&#x000e8;</surname><given-names>E</given-names></name><name><surname>Hevir-Kene</surname><given-names>N</given-names></name><name><surname>Ri&#x0017e;ner</surname><given-names>TL</given-names></name><name><surname>Peternel</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function.</article-title>
<source><italic>Eur J Pharm Sci.</italic></source> (<year>2015</year>) <volume>69</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2014.12.017</pub-id>
<?supplied-pmid 25555374?><pub-id pub-id-type="pmid">25555374</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chidekel</surname><given-names>A</given-names></name><name><surname>Shaffer</surname><given-names>TH.</given-names></name></person-group>
<article-title>Cultured human airway epithelial cells (calu-3): a model of human respiratory function, structure, and inflammatory responses.</article-title>
<source><italic>Crit Care Res Pract.</italic></source> (<year>2010</year>) <volume>2010</volume>:<issue>394578</issue>. <pub-id pub-id-type="doi">10.1155/2010/394578</pub-id>
<?supplied-pmid 20948883?><pub-id pub-id-type="pmid">20948883</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Burkett</surname><given-names>SE</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Pickles</surname><given-names>RJ.</given-names></name></person-group>
<article-title>SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium.</article-title>
<source><italic>Virus Res.</italic></source> (<year>2008</year>) <volume>133</volume>:<fpage>33</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.013</pub-id>
<?supplied-pmid 17451829?><pub-id pub-id-type="pmid">17451829</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>CT</given-names></name><name><surname>Tseng</surname><given-names>J</given-names></name><name><surname>Perrone</surname><given-names>L</given-names></name><name><surname>Worthy</surname><given-names>M</given-names></name><name><surname>Popov</surname><given-names>V</given-names></name><name><surname>Peters</surname><given-names>CJ.</given-names></name></person-group>
<article-title>Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells.</article-title>
<source><italic>J Virol.</italic></source> (<year>2005</year>) <volume>79</volume>:<fpage>9470</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.15.9470-9479.2005</pub-id>
<?supplied-pmid 16014910?><pub-id pub-id-type="pmid">16014910</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Pruijssers</surname><given-names>AJ</given-names></name><name><surname>Agostini</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.</article-title>
<source><italic>Sci Transl Med.</italic></source> (<year>2020</year>) <volume>12</volume>:<issue>eabb5883</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abb5883</pub-id>
<?supplied-pmid 32253226?><pub-id pub-id-type="pmid">32253226</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name></person-group>
<article-title>TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection.</article-title>
<source><italic>J Virol.</italic></source> (<year>2019</year>) <volume>93</volume>:<issue>e01815-18</issue>. <pub-id pub-id-type="doi">10.1128/JVI.01815-18</pub-id>
<?supplied-pmid 30626688?><pub-id pub-id-type="pmid">30626688</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Paddock</surname><given-names>C</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Butler</surname><given-names>E</given-names></name><name><surname>Zaki</surname><given-names>S</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group>
<article-title>Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans.</article-title>
<source><italic>J Virol.</italic></source> (<year>2005</year>) <volume>79</volume>:<fpage>5833</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.9.5833-5838.2005</pub-id>
<?supplied-pmid 15827197?><pub-id pub-id-type="pmid">15827197</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>SR</given-names></name><name><surname>Bao</surname><given-names>LL.</given-names></name></person-group>
<article-title>The battle against SARS and MERS coronaviruses: reservoirs and animal models.</article-title>
<source><italic>Animal Model Exp Med.</italic></source> (<year>2018</year>) <volume>1</volume>:<fpage>125</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/ame2.12017</pub-id>
<?supplied-pmid 30891557?><pub-id pub-id-type="pmid">30891557</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCray</surname><given-names>PB</given-names><suffix>Jr.</suffix></name><name><surname>Pewe</surname><given-names>L</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Manzel</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus.</article-title>
<source><italic>J Virol.</italic></source> (<year>2007</year>) <volume>81</volume>:<fpage>813</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02012-06</pub-id>
<?supplied-pmid 17079315?><pub-id pub-id-type="pmid">17079315</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>LF</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection.</article-title>
<source><italic>Comp Med.</italic></source> (<year>2007</year>) <volume>57</volume>:<fpage>450</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">17974127</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alenina</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>M.</given-names></name></person-group>
<article-title>ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models.</article-title>
<source><italic>Neurochem Res.</italic></source> (<year>2019</year>) <volume>44</volume>:<fpage>1323</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-018-2679-4</pub-id>
<?supplied-pmid 30443713?><pub-id pub-id-type="pmid">30443713</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.</article-title>
<source><italic>Nature.</italic></source> (<year>2020</year>) <volume>583</volume>:<fpage>830</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2312-y</pub-id>
<?supplied-pmid 32380511?><pub-id pub-id-type="pmid">32380511</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Meir</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.05.27.118893</pub-id>
<?supplied-pmid 32577647?><pub-id pub-id-type="pmid">32577647</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>HJ</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Huang</surname><given-names>XY</given-names></name><etal/></person-group>
<article-title>A Mouse Model of SARS-CoV-2infection and pathogenesis.</article-title>
<source><italic>Cell Host Microbe.</italic></source> (<year>2020</year>) <volume>28</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.23880/vij-16000242</pub-id><pub-id pub-id-type="pmid">32645350</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Heinlein</surname><given-names>C</given-names></name><name><surname>Hackman</surname><given-names>RC</given-names></name><name><surname>Nelson</surname><given-names>PS.</given-names></name></person-group>
<article-title>Phenotypic analysis of mice lacking the Tmprss2-encoded protease.</article-title>
<source><italic>Mol Cell Biol.</italic></source> (<year>2006</year>) <volume>26</volume>:<fpage>965</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.26.3.965-975.2006</pub-id>
<?supplied-pmid 16428450?><pub-id pub-id-type="pmid">16428450</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>I</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>S.</given-names></name></person-group>
<article-title>STAT1 knockout mice are highly susceptible to pulmonary mycobacterial infection.</article-title>
<source><italic>Tohoku J Exp Med.</italic></source> (<year>2004</year>) <volume>202</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1620/tjem.202.41</pub-id>
<?supplied-pmid 14738323?><pub-id pub-id-type="pmid">14738323</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meraz</surname><given-names>MA</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Sheehan</surname><given-names>KC</given-names></name><name><surname>Bach</surname><given-names>A</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Dighe</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.</article-title>
<source><italic>Cell.</italic></source> (<year>1996</year>) <volume>84</volume>:<fpage>431</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-867481288-x</pub-id><pub-id pub-id-type="pmid">8608597</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahlak&#x000f5;iv</surname><given-names>T</given-names></name><name><surname>Ritz</surname><given-names>D</given-names></name><name><surname>Mordstein</surname><given-names>M</given-names></name><name><surname>DeDiego</surname><given-names>ML</given-names></name><name><surname>Enjuanes</surname><given-names>L</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread.</article-title>
<source><italic>J Gen Virol.</italic></source> (<year>2012</year>) <volume>93(Pt 12)</volume>:<fpage>2601</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.046284-0</pub-id>
<?supplied-pmid 22956738?><pub-id pub-id-type="pmid">22956738</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Morrison</surname><given-names>TE</given-names></name><name><surname>Whitmore</surname><given-names>A</given-names></name><name><surname>Funkhouser</surname><given-names>W</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism.</article-title>
<source><italic>PLoS Pathog.</italic></source> (<year>2010</year>) <volume>6</volume>:<issue>e1000849</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000849</pub-id>
<?supplied-pmid 20386712?><pub-id pub-id-type="pmid">20386712</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>YQ</given-names></name><etal/></person-group>
<article-title>Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.05.02.073411</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinnon</surname><given-names>IIIKH</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.05.06.081497</pub-id>
<?supplied-pmid 32511406?><pub-id pub-id-type="pmid">32511406</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Rapid development of an inactivated vaccine for SARS-CoV-2.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>] <pub-id pub-id-type="doi">10.1101/2020.04.17.046375</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Hayes</surname><given-names>N</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Zaki</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters.</article-title>
<source><italic>J Virol.</italic></source> (<year>2005</year>) <volume>79</volume>:<fpage>503</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.1.503-511.2005</pub-id>
<?supplied-pmid 15596843?><pub-id pub-id-type="pmid">15596843</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaecher</surname><given-names>SR</given-names></name><name><surname>Stabenow</surname><given-names>J</given-names></name><name><surname>Oberle</surname><given-names>C</given-names></name><name><surname>Schriewer</surname><given-names>J</given-names></name><name><surname>Buller</surname><given-names>RM</given-names></name><name><surname>Sagartz</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>An immunosuppressed Syrian golden hamster model for SARS-CoV infection.</article-title>
<source><italic>Virology.</italic></source> (<year>2008</year>) <volume>380</volume>:<fpage>312</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2008.07.026</pub-id>
<?supplied-pmid 18760437?><pub-id pub-id-type="pmid">18760437</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Yan</surname><given-names>LM</given-names></name><name><surname>Chin</surname><given-names>AWH</given-names></name><name><surname>Fung</surname><given-names>K</given-names></name><name><surname>Choy</surname><given-names>KT</given-names></name><name><surname>Wong</surname><given-names>AYL</given-names></name><etal/></person-group>
<article-title>Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.</article-title>
<source><italic>Nature.</italic></source> (<year>2020</year>) <volume>583</volume>:<fpage>834</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2342-5</pub-id>
<?supplied-pmid 32408338?><pub-id pub-id-type="pmid">32408338</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>AJ</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Poon</surname><given-names>VK</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>AC</given-names></name><etal/></person-group>
<article-title>Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility [published online ahead of print, 2020 Mar 26].</article-title>
<source><italic>Clin Infect Dis.</italic></source> (<year>2020</year>) <volume>20</volume>:<issue>ciaa325</issue>. <pub-id pub-id-type="doi">10.1093/cid/ciaa325</pub-id>
<?supplied-pmid 32215622?><pub-id pub-id-type="pmid">32215622</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>H7N9 influenza viruses are transmissible in ferrets by respiratory droplet.</article-title>
<source><italic>Science.</italic></source> (<year>2013</year>) <volume>341</volume>:<fpage>410</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1126/science.1240532</pub-id>
<?supplied-pmid 23868922?><pub-id pub-id-type="pmid">23868922</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Brand</surname><given-names>JM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Leijten</surname><given-names>L</given-names></name><name><surname>van Riel</surname><given-names>D</given-names></name><name><surname>Martina</surname><given-names>BEE</given-names></name><name><surname>Osterhauset</surname><given-names>ADME</given-names></name><etal/></person-group>
<article-title>Pathology of experimental SARS coronavirus infection in cats and ferrets.</article-title>
<source><italic>Vet Pathol.</italic></source> (<year>2008</year>) <volume>45</volume>:<fpage>551</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1354/vp.45-4-551</pub-id>
<?supplied-pmid 18587105?><pub-id pub-id-type="pmid">18587105</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>YK</given-names></name><name><surname>Ali</surname><given-names>GD</given-names></name><name><surname>Jia</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kelvin</surname><given-names>D</given-names></name><name><surname>Couch</surname><given-names>RC</given-names></name><etal/></person-group>
<article-title>The SARS-CoV ferret model in an infection-challenge study.</article-title>
<source><italic>Virology.</italic></source> (<year>2008</year>) <volume>374</volume>:<fpage>151</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2007.12.032</pub-id>
<?supplied-pmid 18234270?><pub-id pub-id-type="pmid">18234270</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2.</article-title>
<source><italic>Science.</italic></source> (<year>2020</year>) <volume>368</volume>:<fpage>1016</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7015</pub-id>
<?supplied-pmid 32269068?><pub-id pub-id-type="pmid">32269068</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>M</given-names></name><name><surname>Kok</surname><given-names>A</given-names></name><name><surname>de Meulder</surname><given-names>D</given-names></name><name><surname>Bestebroer</surname><given-names>T</given-names></name><name><surname>Lamers</surname><given-names>M</given-names></name><name><surname>Okba</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 is transmitted via contact and via the air between ferrets.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.04.16.044503</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Yu</surname><given-names>KM</given-names></name><etal/></person-group>
<article-title>Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.</article-title>
<source><italic>Cell Host Microbe.</italic></source> (<year>2020</year>) <volume>27</volume>:<fpage>704</fpage>&#x02013;<lpage>9.e2</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.03.023</pub-id>
<?supplied-pmid 32259477?><pub-id pub-id-type="pmid">32259477</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Age-related rhesus macaque models of COVID-19.</article-title>
<source><italic>Animal Model Exp Med.</italic></source> (<year>2020</year>) <volume>3</volume>:<fpage>93</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/ame2.12108</pub-id>
<?supplied-pmid 32318665?><pub-id pub-id-type="pmid">32318665</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group>
<article-title>Animal models for SARS.</article-title>
<source><italic>Adv Exp Med Biol.</italic></source> (<year>2006</year>) <volume>581</volume>:<fpage>463</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-33012-9_83</pub-id><pub-id pub-id-type="pmid">17037579</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Lamirande</surname><given-names>EW</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Jackson</surname><given-names>JP</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Animal models and vaccines for SARS-CoV infection.</article-title>
<source><italic>Virus Res.</italic></source> (<year>2008</year>) <volume>133</volume>:<fpage>20</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.025</pub-id>
<?supplied-pmid 17499378?><pub-id pub-id-type="pmid">17499378</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>SL</given-names></name><name><surname>de Lang</surname><given-names>A</given-names></name><name><surname>van den Brand</surname><given-names>JM</given-names></name><name><surname>Leijten</surname><given-names>JM</given-names></name><name><surname>van IJcken</surname><given-names>WF</given-names></name><name><surname>Eijkemans</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Exacerbated innate host response to SARS-CoV in aged non-human primates.</article-title>
<source><italic>PLoS Pathog.</italic></source> (<year>2010</year>) <volume>6</volume>:<issue>e1000756</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000756</pub-id>
<?supplied-pmid 20140198?><pub-id pub-id-type="pmid">20140198</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gretebeck</surname><given-names>LM</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group>
<article-title>Animal models for SARS and MERS coronaviruses.</article-title>
<source><italic>Curr Opin Virol.</italic></source> (<year>2015</year>) <volume>13</volume>:<fpage>123</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2015.06.009</pub-id>
<?supplied-pmid 26184451?><pub-id pub-id-type="pmid">26184451</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockx</surname><given-names>B</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Herfst</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>T</given-names></name><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>de Meulder</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Comparative pathogenesis Of COVID-19, MERS And SARS in a non-human primate model.</article-title>
<source><italic>Science.</italic></source> (<year>2020</year>) <volume>368</volume>:<fpage>1012</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7314</pub-id>
<?supplied-pmid 32303590?><pub-id pub-id-type="pmid">32303590</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Williamson</surname><given-names>BN</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>L</given-names></name><name><surname>Schulzet</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.</article-title>
<source><italic>Nature.</italic></source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1038/s41586-020-2324-7</pub-id>
<comment>[Epub ahead of print]</comment>. <?supplied-pmid 32396922?><pub-id pub-id-type="pmid">32396922</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Comparison of SARS-CoV-2 infections among 3 species of non-human primates.</article-title>
<source><italic>bioRxiv.</italic></source> (2020). [Preprint]. <pub-id pub-id-type="doi">10.1101/2020.04.08.031807</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bras</surname><given-names>A.</given-names></name></person-group>
<article-title>SARS-CoV-2 causes COVID-19-like disease in cynomolgus macaques.</article-title>
<source><italic>Lab Anim (N Y).</italic></source> (<year>2020</year>) <volume>49</volume>:<issue>174</issue>. <pub-id pub-id-type="doi">10.1038/s41684-020-0571-8</pub-id>
<?supplied-pmid 32424314?><pub-id pub-id-type="pmid">32424314</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.03.13.990036</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Cronin</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</article-title>
<source><italic>Proc Natl Acad Sci USA.</italic></source> (<year>2020</year>) <volume>117</volume>:<fpage>6771</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id>
<?supplied-pmid 32054787?><pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.03.13.990226</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Martinot</surname><given-names>A</given-names></name><name><surname>Mcmahan</surname><given-names>K</given-names></name><name><surname>Mercado</surname><given-names>N</given-names></name><name><surname>Peter</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 infection protects against rechallenge in rhesus macaques.</article-title>
<source><italic>Science.</italic></source> (<year>2020</year>) <volume>20</volume>:<issue>eabc4776</issue>. <pub-id pub-id-type="doi">10.1126/science.abc4776</pub-id>
<?supplied-pmid 32434946?><pub-id pub-id-type="pmid">32434946</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>F</given-names></name><name><surname>Meade-White</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>DR</given-names></name><name><surname>Schulz</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.04.15.043166</pub-id>
<?supplied-pmid 32511319?><pub-id pub-id-type="pmid">32511319</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name></person-group>
<article-title>Progress and prospects on vaccine development against SARS-CoV-2.</article-title>
<source><italic>Vaccines (Basel).</italic></source> (<year>2020</year>) <volume>8</volume>:<issue>E153</issue>. <pub-id pub-id-type="doi">10.3390/vaccines8020153</pub-id>
<?supplied-pmid 32235387?><pub-id pub-id-type="pmid">32235387</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Development of an inactivated vaccine candidate for SARS-CoV-2.</article-title>
<source><italic>Science.</italic></source> (<year>2020</year>) <volume>6</volume>:<issue>eabc1932</issue>. <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>
<?supplied-pmid 32376603?><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramani</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>L</given-names></name><name><surname>Ostermann</surname><given-names>PN</given-names></name><name><surname>Gabriel</surname><given-names>E</given-names></name><name><surname>Abida-Islam</surname><given-names>P</given-names></name><name><surname>M&#x000fc;ller-Schiffmann</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 targets cortical neurons of 3D human brain organoids and shows neurodegeneration-like effects.</article-title>
<source><italic>bioRxiv.</italic></source> (2020). [Preprint]. <pub-id pub-id-type="doi">10.1101/2020.05.20.106575</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Israelow</surname><given-names>B</given-names></name><name><surname>Weizman</surname><given-names>OE</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.06.25.169946</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>A Human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids.</article-title>
<source><italic>Cell Stem Cell.</italic></source> (<year>2020</year>) <volume>27</volume>:<fpage>125</fpage>&#x02013;<lpage>36.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2020.06.015</pub-id>
<?supplied-pmid 32579880?><pub-id pub-id-type="pmid">32579880</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Kleijn</surname><given-names>KMA</given-names></name><name><surname>Zuure</surname><given-names>WA</given-names></name><name><surname>Peijnenborg</surname><given-names>J</given-names></name><name><surname>Heuvelmans</surname><given-names>JM</given-names></name><name><surname>Martens</surname><given-names>GJM.</given-names></name></person-group>
<article-title>Reappraisal of human HOG and MO3.13 cell lines as a model to study oligodendrocyte functioning.</article-title>
<source><italic>Cells.</italic></source> (<year>2019</year>) <volume>8</volume>:<issue>1096</issue>. <pub-id pub-id-type="doi">10.3390/cells8091096</pub-id>
<?supplied-pmid 31533280?><pub-id pub-id-type="pmid">31533280</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>GR</given-names></name><name><surname>Dawson</surname><given-names>G.</given-names></name></person-group>
<article-title>Characterization of a cell line derived from a human oligodendroglioma.</article-title>
<source><italic>Mol Chem Neuropathol.</italic></source> (<year>1992</year>) <volume>16</volume>:<fpage>303</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1007/BF03159976</pub-id>
<?supplied-pmid 1329795?><pub-id pub-id-type="pmid">1329795</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benda</surname><given-names>P</given-names></name><name><surname>Lightbody</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>L</given-names></name><name><surname>Sweet</surname><given-names>W.</given-names></name></person-group>
<article-title>Differentiated rat glial cell strain in tissue culture.</article-title>
<source><italic>Science.</italic></source> (<year>1839</year>) <volume>16</volume>:<issue>1968</issue>.</mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>HH</given-names></name><name><surname>Shi</surname><given-names>JG.</given-names></name></person-group>
<article-title>The complete mitochondrial genome sequence of the rat C6 glioma cell line. Mitochondrial DNA Part A, DNA mapping.</article-title>
<source><italic>Seq Anal.</italic></source> (<year>2016</year>) <volume>27</volume>:<fpage>2188</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3109/19401736.2014.982619</pub-id>
<?supplied-pmid 25492533?><pub-id pub-id-type="pmid">25492533</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Yamate</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>GM</given-names></name><name><surname>Ikuta</surname><given-names>K.</given-names></name></person-group>
<article-title>Susceptibility of human and rat neural cell lines to infection by SARS-coronavirus.</article-title>
<source><italic>Biochem Biophys Res Commun.</italic></source> (<year>2005</year>) <volume>334</volume>:<fpage>79</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2005.06.061</pub-id>
<?supplied-pmid 15992768?><pub-id pub-id-type="pmid">15992768</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbour</surname><given-names>N</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Persistent infection of neural cell lines by human coronaviruses.</article-title>
<source><italic>Adv Exp Med Biol.</italic></source> (<year>1998</year>) <volume>440</volume>:<fpage>575</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-5331-1_75</pub-id><pub-id pub-id-type="pmid">9782332</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbour</surname><given-names>N</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>G</given-names></name><name><surname>Lachance</surname><given-names>C</given-names></name><name><surname>Tardieu</surname><given-names>M</given-names></name><name><surname>Cashman</surname><given-names>NR</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Acute and persistent infection of human neural cell lines by human coronavirus OC43.</article-title>
<source><italic>J Virol.</italic></source> (<year>1999</year>) <volume>73</volume>:<fpage>3338</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.73.4.3338-3350.1999</pub-id>
<?supplied-pmid 10074188?><pub-id pub-id-type="pmid">10074188</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favreau</surname><given-names>DJ</given-names></name><name><surname>Meessen-Pinard</surname><given-names>M</given-names></name><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Human coronavirus-induced neuronal programmed cell death is cyclophilin D dependent and potentially caspase dispensable.</article-title>
<source><italic>J Virol.</italic></source> (<year>2012</year>) <volume>86</volume>:<fpage>81</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.06062-11</pub-id>
<?supplied-pmid 22013052?><pub-id pub-id-type="pmid">22013052</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachance</surname><given-names>C</given-names></name><name><surname>Arbour</surname><given-names>N</given-names></name><name><surname>Cashman</surname><given-names>NR</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Involvement of aminopeptidase N (CD13) in Infection of human neural cells by human coronavirus 229E.</article-title>
<source><italic>J Virol.</italic></source> (<year>1998</year>) <volume>72</volume>:<fpage>6511</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.72.8.6511-6519.1998</pub-id>
<?supplied-pmid 9658094?><pub-id pub-id-type="pmid">9658094</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meessen-Pinard</surname><given-names>M</given-names></name><name><surname>Le Coupanec</surname><given-names>A</given-names></name><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Pivotal role of receptor-interacting protein kinase 1 and mixed lineage kinase domain-like in neuronal cell death induced by the human neuroinvasive coronavirus OC43.</article-title>
<source><italic>J Virol.</italic></source> (<year>2017</year>) <volume>91</volume>:<fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01513-16</pub-id>
<?supplied-pmid 27795420?><pub-id pub-id-type="pmid">27795420</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St-Jean</surname><given-names>JR</given-names></name><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Genetic evolution of human coronavirus OC43 in neural cell culture.</article-title>
<source><italic>Adv Exp Med Biol.</italic></source> (<year>2006</year>) <volume>581</volume>:<fpage>499</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-33012-9_88</pub-id><pub-id pub-id-type="pmid">17037584</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonavia</surname><given-names>A</given-names></name><name><surname>Arbour</surname><given-names>N</given-names></name><name><surname>Yong</surname><given-names>VW</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43.</article-title>
<source><italic>J Virol.</italic></source> (<year>1997</year>) <volume>71</volume>:<fpage>800</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.71.1.800-806.1997</pub-id>
<?supplied-pmid 8985420?><pub-id pub-id-type="pmid">8985420</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>PJ</given-names></name><name><surname>Ekande</surname><given-names>S</given-names></name><name><surname>Cashman</surname><given-names>NR</given-names></name><name><surname>Mounir</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>JN.</given-names></name></person-group>
<article-title>Neurotropism of human coronavirus 229E.</article-title>
<source><italic>Adv Exp Med Biol.</italic></source> (<year>1994</year>) <volume>342</volume>:<fpage>339</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-2996-5_52</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>D</given-names></name><name><surname>Heo</surname><given-names>I</given-names></name><name><surname>Clevers</surname><given-names>H.</given-names></name></person-group>
<article-title>Disease modeling in stem cell-derived 3D organoid systems.</article-title>
<source><italic>Trends Mol Med.</italic></source> (<year>2017</year>) <volume>23</volume>:<fpage>393</fpage>&#x02013;<lpage>410</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2017.02.007</pub-id>
<?supplied-pmid 28341301?><pub-id pub-id-type="pmid">28341301</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Manfrin</surname><given-names>A</given-names></name><name><surname>Lutolf</surname><given-names>MP.</given-names></name></person-group>
<article-title>Progress and potential in organoid research.</article-title>
<source><italic>Nat Rev Genet.</italic></source> (<year>2018</year>) <volume>19</volume>:<fpage>671</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-018-0051-9</pub-id>
<?supplied-pmid 30228295?><pub-id pub-id-type="pmid">30228295</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busquet</surname><given-names>F</given-names></name><name><surname>Hartung</surname><given-names>T</given-names></name><name><surname>Pallocca</surname><given-names>G</given-names></name><name><surname>Rovida</surname><given-names>C</given-names></name><name><surname>Leist</surname><given-names>M.</given-names></name></person-group>
<article-title>Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines.</article-title>
<source><italic>Arch Toxicol.</italic></source> (<year>2020</year>) <volume>94</volume>:<fpage>2263</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-020-02787-2</pub-id>
<?supplied-pmid 32447523?><pub-id pub-id-type="pmid">32447523</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname><given-names>K.</given-names></name></person-group>
<article-title>In vitro and animal models for SARS-CoV-2 research.</article-title>
<source><italic>Trends Pharmacol Sci.</italic></source> (<year>2020</year>) <volume>41</volume>:<fpage>513</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2020.05.005</pub-id>
<?supplied-pmid 32553545?><pub-id pub-id-type="pmid">32553545</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Payant</surname><given-names>N</given-names></name><name><surname>Tomer</surname><given-names>MY</given-names></name><etal/></person-group>
<article-title>Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.05.05.079095</pub-id>
<?supplied-pmid 32511403?><pub-id pub-id-type="pmid">32511403</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Ni</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jinsong</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids.</article-title>
<source><italic>Protein Cell.</italic></source> (<year>2020</year>) <volume>2</volume>:<issue>6</issue>. <pub-id pub-id-type="doi">10.1007/s13238-020-00718-6</pub-id>
<?supplied-pmid 32303993?><pub-id pub-id-type="pmid">32303993</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteil</surname><given-names>V</given-names></name><name><surname>Kwon</surname><given-names>H</given-names></name><name><surname>Prado</surname><given-names>P</given-names></name><name><surname>Hagelkr&#x000fc;ys</surname><given-names>A</given-names></name><name><surname>Wimmer</surname><given-names>RA</given-names></name><name><surname>Stahlet</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2.</article-title>
<source><italic>Cell.</italic></source> (<year>2020</year>) <volume>181</volume>:<fpage>905</fpage>&#x02013;<lpage>13.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id>
<?supplied-pmid 32333836?><pub-id pub-id-type="pmid">32333836</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullen</surname><given-names>CK</given-names></name><name><surname>Hogberg</surname><given-names>HT</given-names></name><name><surname>Bahadirli-Talbott</surname><given-names>A</given-names></name><name><surname>Bishai</surname><given-names>WR</given-names></name><name><surname>Hartung</surname><given-names>T</given-names></name><name><surname>Keuthanet</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2.</article-title>
<source><italic>ALTEX.</italic></source> (<year>2020</year>) <volume>20</volume>:<issue>111</issue>. <pub-id pub-id-type="doi">10.14573/altex.2006111</pub-id>
<?supplied-pmid 32591839?><pub-id pub-id-type="pmid">32591839</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname><given-names>AAF</given-names></name><name><surname>Schafer</surname><given-names>ST</given-names></name><name><surname>Gage</surname><given-names>FH.</given-names></name></person-group>
<article-title>Cellular complexity in brain organoids: Current progress and unsolved issues.</article-title>
<source><italic>Semin Cell Dev Biol.</italic></source> (<year>2020</year>) <volume>20</volume>:<issue>13</issue>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2020.05.013</pub-id>
<?supplied-pmid 32499191?><pub-id pub-id-type="pmid">32499191</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesci</surname><given-names>P</given-names></name><name><surname>Macia</surname><given-names>A</given-names></name><name><surname>Saleh</surname><given-names>A</given-names></name><name><surname>Martin-Sancho</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Snethlage</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Sofosbuvir protects human brain organoids against SARS-CoV-2.</article-title>
<source><italic>bioRxiv.</italic></source> (<year>2020</year>). [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2020.05.30.125856</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Modeling G2019S-LRRK2 sporadic Parkinson&#x02019;s disease in 3D midbrain organoids.</article-title>
<source><italic>Stem Cell Rep.</italic></source> (<year>2019</year>) <volume>12</volume>:<fpage>518</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.stemcr.2019.01.020</pub-id>
<?supplied-pmid 30799274?><pub-id pub-id-type="pmid">30799274</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Feldman</surname><given-names>HM</given-names></name><name><surname>Wen</surname><given-names>HL</given-names></name><name><surname>Penney</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>APOE4 causes widespread molecular and cellular alterations associated with Alzheimer&#x02019;s disease phenotypes in human iPSC-derived brain cell types [published correction appears in Neuron. 2018 Jun 27;98 (6):1294].</article-title>
<source><italic>Neuron.</italic></source> (<year>2018</year>) <volume>98</volume>:<fpage>1141</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.05.008</pub-id>
<?supplied-pmid 29861287?><pub-id pub-id-type="pmid">29861287</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>LM</given-names></name><name><surname>Reinhardt</surname><given-names>L</given-names></name><name><surname>Reinhardt</surname><given-names>P</given-names></name><name><surname>Glatza</surname><given-names>M</given-names></name><name><surname>Monzel</surname><given-names>AS</given-names></name><name><surname>Stanslowskyet</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Modeling Parkinson&#x02019;s disease in midbrain-like organoids.</article-title>
<source><italic>NPJ Parkinsons Dis.</italic></source> (<year>2019</year>) <volume>5</volume>:<issue>5</issue>. <pub-id pub-id-type="doi">10.1038/s41531-019-0078-4</pub-id>
<?supplied-pmid 30963107?><pub-id pub-id-type="pmid">30963107</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>HK</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Grewal</surname><given-names>N</given-names></name><name><surname>Natt</surname><given-names>NK.</given-names></name></person-group>
<article-title>Sofosbuvir: a novel treatment option for chronic hepatitis C infection.</article-title>
<source><italic>J Pharmacol Pharmacother.</italic></source> (<year>2014</year>) <volume>5</volume>:<fpage>278</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.4103/0976-500X.142464</pub-id>
<?supplied-pmid 25422576?><pub-id pub-id-type="pmid">25422576</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>KB</given-names></name><name><surname>Edwards</surname><given-names>RA</given-names></name><name><surname>Romero</surname><given-names>KM</given-names></name><name><surname>Kotlajich</surname><given-names>MV</given-names></name><name><surname>Stohlman</surname><given-names>SA</given-names></name><name><surname>Lane</surname><given-names>TE.</given-names></name></person-group>
<article-title>Expression of CXC chemokine ligand 10 from the mouse hepatitis virus genome results in protection from viral-induced neurological and liver disease.</article-title>
<source><italic>J Immunol.</italic></source> (<year>2007</year>) <volume>179</volume>:<fpage>1155</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.2.1155</pub-id>
<?supplied-pmid 17617609?><pub-id pub-id-type="pmid">17617609</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarin</surname><given-names>C</given-names></name><name><surname>Bergmann</surname><given-names>CC.</given-names></name></person-group>
<article-title>Fine tuning the cytokine storm by IFN and IL-10 following neurotropic coronavirus encephalomyelitis.</article-title>
<source><italic>Front Immunol.</italic></source> (<year>2018</year>) <volume>9</volume>:<issue>3022</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.03022</pub-id>
<?supplied-pmid 30619363?><pub-id pub-id-type="pmid">30619363</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wege</surname><given-names>H</given-names></name><name><surname>Schluesener</surname><given-names>H</given-names></name><name><surname>Meyermann</surname><given-names>R</given-names></name><name><surname>Barac-Latas</surname><given-names>V</given-names></name><name><surname>Suchanek</surname><given-names>G</given-names></name><name><surname>Lassmann</surname><given-names>H.</given-names></name></person-group>
<article-title>Coronavirus infection and demyelination. Development of inflammatory lesions in Lewis rats.</article-title>
<source><italic>Adv Exp Med Biol.</italic></source> (<year>1998</year>) <volume>440</volume>:<fpage>437</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-5331-1_55</pub-id><pub-id pub-id-type="pmid">9782312</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalinger</surname><given-names>ZB</given-names></name><name><surname>Elliott</surname><given-names>R</given-names></name><name><surname>Weiss</surname><given-names>SR.</given-names></name></person-group>
<article-title>Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus.</article-title>
<source><italic>J Neurovirol.</italic></source> (<year>2017</year>) <volume>23</volume>:<fpage>845</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1007/s13365-017-0574-4</pub-id>
<?supplied-pmid 28895072?><pub-id pub-id-type="pmid">28895072</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruslin</surname><given-names>E</given-names></name><name><surname>Moisan</surname><given-names>S</given-names></name><name><surname>St-Pierre</surname><given-names>Y</given-names></name><name><surname>Desforges</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Transcriptome profile within the mouse central nervous system and activation of myelin-reactive T cells following murine coronavirus infection.</article-title>
<source><italic>J Neuroimmunol.</italic></source> (<year>2005</year>) <volume>162</volume>:<fpage>60</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.01.007</pub-id>
<?supplied-pmid 15833360?><pub-id pub-id-type="pmid">15833360</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KS</given-names></name><name><surname>Aizaki</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>MM.</given-names></name></person-group>
<article-title>Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release.</article-title>
<source><italic>J Virol.</italic></source> (<year>2005</year>) <volume>79</volume>:<fpage>9862</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.15.9862-9871.2005</pub-id>
<?supplied-pmid 16014947?><pub-id pub-id-type="pmid">16014947</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>RS</given-names></name><name><surname>Dine</surname><given-names>K</given-names></name><name><surname>Das Sarma</surname><given-names>J</given-names></name><name><surname>Shindler</surname><given-names>KS.</given-names></name></person-group>
<article-title>Intracranial inoculation is more potent than intranasal inoculation for inducing optic neuritis in the mouse hepatitis virus-induced model of multiple sclerosis.</article-title>
<source><italic>Front Cell Infect Microbiol.</italic></source> (<year>2018</year>) <volume>8</volume>:<issue>311</issue>. <pub-id pub-id-type="doi">10.3389/fcimb.2018.00311</pub-id>
<?supplied-pmid 30234031?><pub-id pub-id-type="pmid">30234031</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>FI</given-names></name><name><surname>Stohlman</surname><given-names>SA</given-names></name><name><surname>Fleming</surname><given-names>JO.</given-names></name></person-group>
<article-title>Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated.</article-title>
<source><italic>J Neuroimmunol.</italic></source> (<year>1990</year>) <volume>30</volume>:<fpage>31</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/0165-5728(90)90050-w</pub-id><pub-id pub-id-type="pmid">2172304</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandekar</surname><given-names>AA</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group>
<article-title>Virus-induced demyelination in nude mice is mediated by gamma delta T cells.</article-title>
<source><italic>Am J Pathol.</italic></source> (<year>2002</year>) <volume>161</volume>:<fpage>1255</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9440(10)64402-1</pub-id><pub-id pub-id-type="pmid">12368199</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>WG</given-names></name><name><surname>Chen</surname><given-names>BP</given-names></name><name><surname>Liu</surname><given-names>MT</given-names></name><name><surname>Lane</surname><given-names>TE.</given-names></name></person-group>
<article-title>Mouse hepatitis virus infection of the central nervous system: chemokine-mediated regulation of host defense and disease.</article-title>
<source><italic>Viral Immunol.</italic></source> (<year>2002</year>) <volume>15</volume>:<fpage>261</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1089/08828240260066215</pub-id>
<?supplied-pmid 12081011?><pub-id pub-id-type="pmid">12081011</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>TE</given-names></name><name><surname>Hosking</surname><given-names>MP.</given-names></name></person-group>
<article-title>The pathogenesis of murine coronavirus infection of the central nervous system.</article-title>
<source><italic>Crit Rev Immunol.</italic></source> (<year>2010</year>) <volume>30</volume>:<fpage>119</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1615/critrevimmunol.v30.i2.20</pub-id>
<?supplied-pmid 20370625?><pub-id pub-id-type="pmid">20370625</pub-id></mixed-citation></ref></ref-list></back></article>